

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

C12N 15/31

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>4</sup> : C12N 15/00, A61K 39/04 G01N 33/569	A2	(11) International Publication Number: WO 88/ 05823 (43) International Publication Date: 11 August 1988 (11.08.88)
(21) International Application Number: PCT/US88/00281 (22) International Filing Date: 1 February 1988 (01.02.88) (31) Priority Application Number: 010,007 (32) Priority Date: 2 February 1987 (02.02.87) (33) Priority Country: US	(74) Agents: GRANAHAN, Patricia et al.: Hamilton, Brook, Smith & Reynolds, Two Militia Drive, Lexington, MA 02173 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).	
Applicant: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH [US/US]: Nine Cambridge Center, Cambridge, MA 02142 (US). Inventors: HUSSON, Robert. N. : 60 Parkman Street, Brookline, MA 02146 (US). YOUNG, Richard. A. : 11 Sussex Road, Winchester, MA 01890 (US). SHINNICK, Thomas. M. : 1434 Rainier Falls Drive, Atlanta, GA 30329 (US).		Published Without international search report and to be republished upon receipt of that report.

(54) Title: MYCOBACTERIUM TUBERCULOSIS GENES ENCODING PROTEIN ANTIGENS

## (57) Abstract

*Mycobacterium tuberculosis* genes encoding five immunologically relevant proteins have been isolated by systematically screening a lambda gt11 recombinant DNA expression library with a collection of murine monoclonal antibodies directed against protein antigens of this pathogen. One of the *M. tuberculosis* antigens, a 65kD protein, has been shown to have determinants common to *M. tuberculosis* and *M. leprae*. In addition, genes encoding proteins of other mycobacteria (*M. africanum*, *M. smegmatis*, *M. bovis* BCG and *M. avium*) have been isolated. Isolation and characterization of genes encoding major protein antigens of *M. tuberculosis* make it possible to develop reagents useful in the diagnosis, prevention and treatment of tuberculosis. They can be used, for example, in the development of skin tests, serodiagnostic tests and vaccines specific for tuberculosis.

AN

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

-1-

MYCOBACTERIUM TUBERCULOSIS GENES AND  
ENCODING PROTEIN ANTIGENS

Description

Background

05        Tuberculosis was the major cause of infectious  
mortality in Europe and the United States in the  
19th and early 20th centuries. Dubos, R. and J.  
Dubos, The White Plague: Tuberculosis, Man and  
10        Society, Little Brown & Co., Boston, MA, (1952).  
Today, it remains a significant global health  
problem.

For example, in the United States there are  
over 20,000 new cases of tuberculosis diagnosed  
annually. In addition, the steadily declining  
15        incidence of tuberculosis evident in preceding years  
appears to have changed course, reaching a plateau  
in 1985 and showing an increase in the first half of  
1986. Centers for Disease Control, Morbidity/Mor-  
20        tality, Weekly Report, 34:774 (1986); and Centers  
for Disease Control, Morbidity/Mortality, Weekly  
Report, 35:774 (1986).

Worldwide, tuberculosis remains widespread and  
constitutes a health problem of major proportions,  
particularly in developing countries. The World  
25        Health Organization estimates that there are ten  
million new cases of active tuberculosis per year  
and an annual mortality of approximately three

-2-

million. Joint International Union Against Tuberculosis and World Health Organization Study Group, Tubercle, 63:157-169 (1982).

05 Tuberculosis is caused by Mycobacterium (M.)  
tuberculosis or Mycobacterium (M.) bovis, which are  
the 'tubercle bacilli' of the family Mycobacteri-  
aceae. M. bovis is a species which causes tubercu-  
10 losis in cattle and is transmissible to humans and  
other animals, in whom it causes tuberculosis. At  
present, nearly all tuberculosis is caused by  
respiratory infection with M. tuberculosis. Infec-  
tion may be asymptomatic in some, but in other  
15 individuals, it produces pulmonary lesions which  
lead to severe debilitation or death. Resistance to  
tuberculosis is provided by cell-mediated immune  
mechanisms.

Mycobacteria are aerobic, acid-fast, non-spore-  
forming, non-motile bacilli with high lipid contents  
and slow generation times. M. leprae is the eti-  
20 ologic agent of leprosy and, among the other myco-  
bacteria, the only major pathogen. Bloom, B.R. and  
T. Godal, Review of Infectious Diseases, 5:765-780  
(1983). However, other mycobacterial species are  
capable of causing disease. Wallace, R.J. et.al.,  
25 Review of Infectious Diseases, 5:657-679 (1984).  
M. avium, for example, causes tuberculosis in fowl  
and in other birds. Members of the M.  
Avium-intracellularae complex have become important  
pathogens among individuals with acquired immuno-  
30 deficiency syndrome (AIDS). Certain groups of

-3-

individuals with AIDS have a markedly increased incidence of tuberculosis-as well. Pitchenik, A.E. et. al., Annals of Internal Medicine, 101:641-645 (1984).

05       Diagnostic and immunoprophylactic measures for mycobacterial diseases have changed little in the past half century. Tuberculin, developed by Koch as a cure for tuberculosis in the late 1800s, is an M. tuberculosis filtrate of complex and poorly-defined  
10       composition. It is used as a skin test antigen to detect prior exposure to the bacillus. Enrichment of the protein fraction of this material in the 1930's produced the purified protein derivative (PPD) which is still used to diagnose exposure to  
15       tuberculosis. Seibert, F.M. et.al., American Review of Tuberculosis, 30(Suppl.):705-778 (1934). Its usefulness is limited, however, by its lack of specificity and its inability to distinguish active disease from prior sensitization by contact with M. tuberculosis or cross-sensitization to other myco-  
20       bacteria. Young, R.A. and R.W. Davis, Proceedings of the National Academy of Sciences, USA, 80:194-1198 (1983).

25       Bacille Calmette Guerin (BCG), an avirulent strain of M. bovis, has been used widely as a live vaccine against tuberculosis for over 50 years. Calmette, A., C. et.al., Bulletin of the Academy of

-4-

05 Medicine Paris, 91:787-796 (1924). During that  
time, numerous studies have shown that BCG has  
protective efficacy against tuberculosis. These  
studies are reviewed by F. Luelmo in American Review  
10 of Respiratory Diseases, 125(pt. 2):70-72 (1982).  
However, more recently, a major trial of BCG in  
India indicated that such a vaccine was not protec-  
tive against tuberculosis in this setting. World  
15 Health Organization WHO Technical Report Series, 651  
(1980). Presently available approaches to diagnos-  
ing, preventing and treating tuberculosis are  
limited in their effectiveness and must be improved  
if a solution is to be found for the important  
public health problem tuberculosis represents  
worldwide.

#### Summary of the Invention

20 The present invention is based on the isolation  
of genes encoding immunogenic protein antigens of  
the tubercle bacillus Mycobacterium tuberculosis (M.  
tuberculosis). Genes encoding such protein antigens  
have been isolated from a recombinant DNA expression  
library of M. tuberculosis DNA. Genes encoding  
proteins of four additional mycobacteria have also  
been isolated and restriction maps produced.

25 In particular, genes encoding five immunodomi-  
nant protein antigens of the tuberculosis bacillus  
(i.e., those M. tuberculosis proteins of molecular  
weight 12,000 daltons (12kD), 14kD, 19kD, 65kD and  
71kD have been isolated by probing a lambda gt11  
30 expression library of M. tuberculosis DNA with

-5-

monoclonal antibodies directed against M. tuberculosis-specific antigens.

05 Recombinant DNA clones producing the specific antigenic determinants recognized by the monoclonal  
antigens were also isolated in this manner. DNA  
from such recombinant lambda gt11 clones was mapped  
with restriction endonucleases; the restriction maps  
for genes encoding the five immunodominant protein  
10 antigens (i.e., genes encoding the 12kD, 14kD, 19kD, 65kD and 71kD proteins) were deduced. The nucleotide  
sequence of three of the genes have been determined  
and, in each case, the amino acid sequence of  
the encoded protein has been deduced.

#### Brief Description of the Drawings

15 Figure 1 shows restriction maps of M. tuberculosis DNA. Recombinant DNA clones isolated with  
monoclonal antibodies directed against the 12kD,  
14kD, 19kD, 65kD and 71kD protein antigens were  
mapped with restriction endonucleases. The insert  
20 DNA endpoints are designated left (L) or right (R)  
in relation to lac Z transcripts which traverse the  
insert from right to left. Restriction sites are  
represented as follows: A, Sal I; B, BamHI; E,  
EcoRI; G, BglIII; K, KpnI; P, PvuI; S, SacI; X, XhoI.

25 Figure 2 shows arrays of antigens from M. tuberculosis recombinant DNA clones probed with  
rabbit hyperimmune serum. The code of the recombinant  
DNA clones shown on the numbers filter is: 1,  
Y3275; 2, Y3274; 3, Y3279; 4, Y3277; 5, Y3247; 6,  
30 Y3272; 7, Y3150; 8, Y3254; 9, Y3147; 10, Y3163; 11,

-6-

Y3179; 12, Y3191; 13, Y3252; 14, Y3178; 15, Y3180; 16, Y3143; 17, lambda gt11. Clones 1, 5, 6, 7, 9 and 16 are M. tuberculosis recombinants described in the following section. Clones 10, 11, 14 and 15 are M. leprae recombinants expressing epitopes of the 18kD, 28kD, 36kD and 65kD antigens, respectively. Clones 2, 3, 4, 8, 12, 13 are uncharacterized recombinants from the lambda gt11 M. tuberculosis and M. leprae libraries. Clone 17 is a non-recombinant lambda gt11 control.

Figure 3 shows arrays of recombinant mycobacterial antigens probed with monoclonal antibodies to assess the extent of cross-reactivity between recombinant protein antigen of M. tuberculosis and of M. leprae. The array of clones is identical to that shown in Figure 2. Antibody probes and the antigen sizes recognized are: 1, IT-11 (71kD); 2, IT-31 (65kD); 3, IT-16 (19kD); 4, IT-1 (14kD); 5, IT-3 (12kD).

Figure 4 shows restriction maps of DNA encoding four proteins (71kD, 65kD, 19kD and 14kD) of M. tuberculosis and four proteins (71kD, 65kD, 19kD and 14kD) of M. bovis BCG. Restriction sites are represented as follows: A, AatII; B, BamHI; C, BclI; D, DraIII; E=EcoRI; G, BglII; H, HinfI; K, KpnI; P, PstI; S, SalI; V, PvuI and X, XhoI.

Figure 5 is a comparison of restriction maps of the gene encoding the 65kD protein of 6 mycobacteria (M. leprae, M. tuberculosis, M. africanum, M. bovis BCG, M. smegmatis, M. avium). Restriction sites are



-7-

as follows: B, BamHI; K, KpnI; N, SacI; P, PvuI; S, SalI; X, XhoI.

Figure 6 is the nucleotide sequence of the region containing the M. tuberculosis 19kD gene. The deduced amino acid sequence of the encoded protein is also represented (protein start position, nucleotide 1110; protein stop position, nucleotide 1586).

Figure 7 is the nucleotide sequence of the region containing the M. tuberculosis 71kD gene and the deduced amino acid sequence of the encoded protein.

Figure 8 is the nucleotide sequence of the region containing the M. tuberculosis 65kD gene. The deduced amino acid sequences of the two long open reading frames are presented in one letter code over (540) or under (517) the appropriate triplets.

#### Detailed Description of the Invention

The invention described herein is based on the isolation of genes encoding immunogenic protein antigens of the bacillus M. tuberculosis, which is the major etiologic agent of tuberculosis. In particular, it is based on the isolation, using monoclonal antibodies directed against M. tuberculosis-specific antigens, of genes encoding five immunogenic protein antigens of the tuberculosis bacillus; these five antigens are immunodominant. Immunogenic antigens are those which elicit a response from the immune system. Immunodominant protein antigens are immunogenic

-8-

antigens against which the immune system directs a significant portion of its response. Genes encoding M. tuberculosis antigens of molecular weight 12,000 daltons (12kD), 14kD, 19kD, 65kD and 71kD were isolated in this manner.

Isolation and characterization of major protein antigens of M. tuberculosis, as described herein, make it possible to develop more effective tools for the prevention, diagnosis, and treatment of tuberculosis. Identification and isolation of genes encoding five immunodominant M. tuberculosis protein antigens, as well as of the five protein antigens, are described below; uses of the genes and encoded products are also described.

M. bovis BCG DNA clones were also isolated for the genes encoding the 71kD, 65kD, 19kD and 14kD proteins. In order to compare M. bovis BCG and M. tuberculosis genes encoding proteins of similar molecular weight, restriction endonuclease maps were determined for DNA segments containing each of the genes. Restriction maps for each of these genes is represented in Figure 4.

In addition, DNA clones were isolated for the genes encoding the 65kD protein from M. africanum, M. smegmatis and M. avium. Restriction endonuclease maps were determined for DNA segments containing each of these genes. The restriction maps for these genes, as well as for the genes encoding the 65kD protein of M. tuberculosis, M. bovis BCG and M. leprae, are represented in Figure 5.

-9-

I. Construction of a recombinant expression library of M. tuberculosis DNA

A recombinant DNA expression library of M. tuberculosis DNA was constructed using lambda gt11. The library was constructed with M. tuberculosis genomic DNA fragments in such a way that all protein-coding sequences would be represented and expressed. Young, R.A., B.R. Bloom, C.M. Grosskinsky, J. Ivanyi, D. Thomas and R.W. Davis, Proceedings of the National Academy of Sciences, USA, 82:2583-2587 (1985).

Lambda gt11 is a bacteriophage vector which is capable of driving the expression of foreign insert DNA with E. coli transcription and translation signals. Lambda gt11 expresses the insert DNA as a fusion protein connected to the E. coli Beta-galactosidase polypeptide. This approach ensures that the foreign DNA sequence will be efficiently transcribed and translated in E. coli. This approach is also useful in addressing the problem of the highly unstable nature of most foreign proteins; fusion proteins are often more resistant to proteolytic degradation than is the foreign polypeptide alone. Lambda gt11 and the E. coli strain used (Y1090) have been described previously. Young, R.A. et al., Proceedings of the National Academy of Sciences, USA, 80:1194-1198 (1983); Young, R.A. and R.W. Davis, Science, 222:778-782 (1983). The teachings of these publications are incorporated herein by reference. The library constructed in this manner has a titer of  $1 \times 10^{10}$  pfu/ml. and

-10-

contains approximately 40% recombinants with an average insert size of 4kB.

II. Screening of the lambda gt11 *M. tuberculosis* library with antibody probes

05 Murine monoclonal antibodies to protein antigens of *M. tuberculosis* were used individually to probe the *M. tuberculosis* recombinant DNA library. This work is described below and with specific  
10 reference to the 65kD antigen in the Exemplification. The antibodies used as probes and the sizes of the antigens to which they bind are shown below.

*M. tuberculosis*

	<u>Antibody</u>	<u>Antigen</u>
	IT-3	12kD
15	IT-20	14kD
	IT-19	19kD
	IT-27	19kD
	IT-17	23kD
	IT-29	23kD
20	IT-15	38kD
	IT-21	38kD
	IT-23	38kD
	IT-13	65kD
	IT-31	65kD
25	IT-33	65kD
	IT-11	71kD

Engers, H.D. et al., Infectious Immunology,  
51:718-720 (1986).

-11-

All monoclonal antibodies were used at approximately 1:200 to 1:300 dilution in 50mM Tris-HCl pH8/150 mM NaCl/.05% Tween 20.

Screening of the lambda gt11 recombinant DNA library was performed as described by Young et al. in Proceedings of the National Academy of Sciences, USA, 82:2583-2587 (1985), the teachings of which are incorporated herein by reference. One modification was made in the method described by Young and co-workers: 1% bovine serum albumin was used in place of 20% fetal calf serum to decrease background.

Briefly, cloned lambda gt11 recombinants were arrayed on lawns of E. coli Y1090. The phage were grown, antigen expression was induced and the antigens were blotted and probed with serum. Detection of signal-producing plaques was performed with a biotinylated secondary antibody system (Vectastain, Vector Laboratories, Burlingame, CA) or with an alkaline phosphatase conjugated secondary antibody system (Protoplot, Promega Biotec, Madison, WI), both used according to manufacturer's instructions. Signal-producing clones were isolated using antibodies directed against protein antigens of molecular weight 12kD, 14kD, 19kD and 65kD and 71kD. In each case, similar numbers of clones were isolated in screens of approximately  $10^5$  recombinant plaques. DNA clones encoding the 23kD and 38kD antigens could not be detected with these antibodies, possibly because the native epitope is modified or topographically complex, or because the

-12-

antigen-antibody interaction is too weak to be recognized by current detection methods.

III. Probing of Arrays of lambda gt11 DNA  
Clones with Antibody Probes

05        0.2 ml of a saturated culture of Y1090 was  
added to 2.5 ml of molten LB soft agar, poured onto  
100 mm plates containing 1.5% LB agar and allowed to  
harden at room temperature for 10 min. 100 ul of  
phage plate stock containing approximately  $10^{11}$   
10 pfu/ml of the lambda gt11 DNA clones of interest  
were placed into alternate wells of 96-well tissue  
culture plates. A multi-pronged transfer device was  
placed briefly in the wells containing phage and  
then touched lightly to the surface of the plate  
15 onto which the soft agar had been poured. The  
plates were then incubated at 42°C for approximately  
3 hours, at which point clear plaques approximately  
5mm in diameter were visible. The plates were then  
overlayed with nitrocellulose filters saturated with  
20 10mM isopropylthiogalactoside (IPTG) and incubated  
at 37°C for 3.5 hours. Subsequent processing of  
filters for detection of antigen was identical to  
the procedures described for screening of lambda  
gt11 library with antibody probes.

25        Immunoscreening of the lambda gt11 library to  
isolate clones reactive with monoclonal antibodies  
specific for the 65kD antigen is described in the  
Exemplification.

-13-

IV. Recombinant DNA Manipulation

DNA from recombinant lambda gt11 clones was isolated and mapped with restriction endonucleases by standard techniques. Davis, R.W. et al.,  
05 Advanced Bacterial Genetics: A Manual for Genetic Engineering, Cold Spring Harbor (1980).

Figure 1 shows the genomic DNA restriction map deduced for each of the genes encoding the five M. tuberculosis antigens and illustrates how each of  
10 the cloned DNAs aligns with that map. All clones isolated with monoclonal antibodies directed against any single antigen align with a single genomic DNA segment. This indicates that all clones were  
15 isolated because they express the protein of interest rather than an unrelated polypeptide containing a similar or identical epitope. In addition, this result suggests that each antigen is the product of a single gene.

The orientation of each DNA insert in the  
20 recombinant clones was determined by restriction analysis. Only among the clones for the 65kD antigen were the inserts found in both possible orientations relative to the direction of lac Z transcription in lambda gt11. This suggests that  
25 this protein can be expressed in E. coli from signals independent of those provided by lac Z. Similar results have been obtained for recombinant DNA clones encoding the 65kD antigens of M. bovis and M. leprae. Thole, J.E.R. et al., Infectious  
30 Immunology, 50:800-806 (1985); Young, R.A. et al., Nature, 316:450-452 (1985).

-14-

The nucleotide sequences of three regions of the M. tuberculosis DNA were determined: 1) the region containing the M. tuberculosis 19kD gene; 2) the region containing the M. tuberculosis 71kD gene; and 3) the region containing the 65kD gene. The three sequences are represented in Figures 6-8. Sequences were determined using standard techniques, which are described in the Exemplification.

#### V. Filter hybridization of Insert DNA

Arrays of lambda gtl1 clones were created as described above and incubated at 42° for 5 hours. The plates were then overlaid with nitrocellulose filters and placed at 4°C for 1 hour. Probe DNA was labelled with <sup>32</sup>P by nick translation. Filter hybridization was performed as described by Davis et al. in Advanced Bacterial Genetics: A Manual for Genetic Engineering, Cold Spring Harbor (1980), the teachings of which are incorporated herein by reference. Hybridization conditions were as follows: 50% v/v formamide, 5x SSPE (1x SSPE is 0.18M NaCl, 10mM Na<sub>1.5</sub>H<sub>1.5</sub>PO<sub>4</sub>, 1mM Na<sub>2</sub> EDTA, pH 7.0), 1x Denhardt's solution (0.02% w/v Ficoll, 0.02% w/v polyvinylpyrrolidone, 0.02% w/v bovine serum albumin), 0.3% NaDodSO<sub>4</sub> at 42°C for approximately 16 hours, followed by washing in 2x SSPE, 0.2% NaDodSO<sub>4</sub> at 45°C.

#### VI. Recombinant Antigens Recognized by Rabbit Serum

The response of a second animal to an antigen preparation of M. tuberculosis was assessed by



-15-

examining the reactivity of rabbit anti-M. tuberculosis hyperimmune sera with recombinant antigens. Cloned lambda gt11 recombinants were arrayed on lawns of E. coli and probed with the rabbit hyper-immune serum. Anti-M. tuberculosis hyperimmune serum, produced by repeated immunization of rabbits with M. tuberculosis H37Rv culture filtrate, was provided by J. Bennedsen (Statens Seruminstitut, Copenhagen, Denmark). These sera were used at 1:100 dilution.

These sera produced positive signals with lambda gt11 clones encoding each of the five M. tuberculosis epitopes which had been isolated with murine monoclonal antibodies (Figure 2). Particularly strong signals were observed with the 65kD and 71kD antigens (Figure 2). These results demonstrate that mice and rabbits can mount an antibody response to the same protein antigens of M. tuberculosis.

Clones for the five M. tuberculosis antigens were detected at similar frequencies in the lambda gt11 recombinant DNA library. Thus, the number and type of antigen-producing clones isolated with polyclonal serum antibodies should reflect the relative titer and diversity of the individual antibodies in this serum.

To determine whether any of the 5 M. tuberculosis antigens are relatively immunodominant in the rabbit humoral immune response to M. tuberculosis, the M. tuberculosis lambda gt11 recombinant DNA library was screened with the rabbit serum. Forty signal-producing clones were isolated, arrayed on

-16-

lawns of E. coli Y1090 and probed with monoclonal antibodies directed against each of the 5 recombinant M. tuberculosis protein antigens. Remarkably, 17 of the 40 clones (43%) reacted strongly with at least one of the four anti-65kD monoclonal antibodies tested. An additional six clones (15%) reacted strongly with the anti-17kD monoclonal antibody (IT-11). This indicates that a large proportion of the anti-M. tuberculosis antibody present in the rabbit serum was directed against the 65kD antigen of M. tuberculosis and suggests that it is a dominant antigen for the rabbit humoral immune response. Seventeen of the clones did not react with any of the monoclonal antibodies tested, suggesting that the rabbit sera may identify M. tuberculosis proteins not recognized by the murine antibodies.

#### VII. Antigenic Relatedness of M. tuberculosis and M. leprae Proteins

There is evidence that M. tuberculosis and M. leprae share immunologically important antigens. To assess this further, an investigation of the exact nature of the immunological relatedness among recombinant protein antigens of M. tuberculosis and M. leprae was conducted.

For each of five M. tuberculosis and four M. leprae protein antigens, a single recombinant DNA clone containing most or all of the gene of interest was used to express antigen in the following manner. The recombinant phage clones were arrayed on a lawn

-17-

of E. coli Y1090, which was then grown and induced for antigen expression. --

Antigen immobilized on nitrocellulose filters was then probed with 26 individual anti-M. tuberculosis and M. leprae monoclonal antibodies. Figure 3 shows the array of DNA clones used and the results obtained with the anti-M tuberculosis antibodies IT-1, IT-3, IT-11, IT-16, and IT-31, which recognized proteins of 14kD, 12kD, 71kD, 19kD and 65kD respectively. Table 1 details the full results of these cross-screening experiments, showing the reactivity of antigen expressed from individual recombinant DNA clones with each of the individual monoclonal antibodies. Clones were scored as positive only if the signal produced was clearly greater than the background signal produced by the non-recombinant lambda gt11 clone included in each array.

-18-

TABLE 1

Reactivity of Monoclonal Antibodies with  
Recombinant Protein Antigens

[illegible]

-19-

Several conclusions can be drawn from the results shown in Table 1. Among the 11 monoclonal antibodies that recognize a 65kD antigen, 7 react with the 65kD protein from both mycobacteria (IT-31, C1.1, IIH9 (identical to IT-33), IIC8, T2.3, Y1-2, SA2.D7C), one antibody reacts only with the M. tuberculosis 65kD protein (IT-13), and two antibodies react only with the M. leprae 65kD protein (IIIE9 and IIIC8). One antibody, ML30A, cross-reacts with an antigen in E. coli and could not specifically identify antigen-producing clones. These results indicate that the 65kD protein antigens of M. tuberculosis and M. leprae are homologues and share a number of epitopes. In addition to these shared epitopes, however, both 65kD antigens have epitopes that are specific for one species relative to the other.

No cross-reactivity was observed between other antigens of these two mycobacterial species. Because monoclonal antibodies recognize a single epitope and because only one or a few antibodies were available for each antigen, it is not clear whether the 65kD proteins are the only homologous protein antigens of M. tuberculosis and M. leprae. Among the antigens for which lambda gt11 clones have been isolated, the 18kD antigen of M. leprae and the 19kD antigen of M. tuberculosis are of similar size. To determine whether these two antigens are related, the homology of the DNA sequences that encode these antigens was examined. At conditions of moderate stringency, no hybridization was observed between

-20-

the insert DNA and Y3147 (an M. tuberculosis 19kD clone) and Y3179 (an M. leprae 18kD clone). This indicates no significant homology between the DNA sequences of the insert DNAs of these two clones.

05 This result suggests that the M. tuberculosis 19kD and the M. leprae 18kD proteins are unlikely to be homologous.

As a result of the work described, recombinant DNA clones encoding five major protein antigens of

10 M. tuberculosis were isolated through the use of an extensive collection of well-characterized murine monoclonal antibodies. These five proteins were also found to be major antigens in the rabbit humoral immune response to M. tuberculosis. One of

15 these antigens, the 65kD protein, is shared with another other mycobacterial pathogen M. leprae.

Several lines of evidence indicate that the 65kD antigen is among the most immunodominant of the protein antigens of M. tuberculosis. Eleven of the

20 25 different M. tuberculosis and M. leprae monoclonal antibodies examined in this study recognized the 65kD recombinant antigen from one or both mycobacteria. In addition, almost half of the recombinant DNA clones isolated with rabbit poly-

25 clonal anti-M. tuberculosis sera express the 65kD antigen, reflecting the predominance of antibody to this antigen in these sera.

Considerable evidence indicates that the 65kD antigen plays an important role in the human re-

30 sponse to tuberculosis. Antibodies directed against this protein can be detected in the serum of

-21-

patients with tuberculosis. The 65kD antigen is present in purified protein derivatives (PPD's) of M. tuberculosis, M. bovis, and other mycobacteria. Thole, J.E.R. et al., Infection Immunity, 50:800-806 (1985). Finally, helper T cell clones reactive with recombinant 65kD antigen have been isolated from patients with tuberculosis, indicating that this antigen is involved in the cell-mediated as well as the humoral immune response to tuberculosis.

Among the major antigens of the leprosy bacillus, the 65kD antigen appears to elicit antibody and T cell responses similar to those observed for the M. tuberculosis antigen. Both serum antibodies and T cells directed against the 65kD M. leprae antigen have been observed in patients with leprosy. Britton, W.J. et al., Journal of Immunology, 135:4171-4177 (1985); Mustafa, A.S. et al., Nature, 319:63-66 (1986). In addition, T cell clones from leprosy patients have been found to respond to recombinant 65kD protein of M. bovis, as well as to PPD's from both M. bovis BCG and M. leprae. Emmrich, F. et al., Journal of Experimental Medicine, 163:1024-1029 (1986); Shankar, P. et al., Journal of Immunology, 136:4255-4263 (1986). It is interesting to note that in vaccine trials in Asia and Africa, BCG provided significant protection against leprosy, ranging from 20% to 80%. Fine, P., Tubercle, 65:137-153 (1984). An intriguing possibility is that the M. bovis BCG 65kD antigen is involved in engendering the immune protection

-22-

provided by this vaccine against M. leprae, as well as against M. tuberculosis.

05 In addition to the 65kD antigen, there is evidence that the 19kD and 71kD antigens of M. tuberculosis may be particularly important in the immune response to this bacillus. Helper T cell clones from tuberculosis patients have been isolated which respond to the recombinant 19kD protein. The 71kD antigen is recognized by the humoral immune system of both mice and rabbits, and antibody to this antigen has been shown to be a prominent component of hyperimmune anti-M. tuberculosis rabbit sera.

15 VIII. Isolation of DNA Clones for Genes Encoding Proteins of Additional Mycobacteria

Using the procedures described above for isolation of genes encoding M. tuberculosis proteins, genes encoding proteins of additional mycobacteria were isolated. DNA clones containing genes encoding the following proteins were isolated:

	<u>Mycobacterium</u>	<u>Protein</u>	<u>Clone</u>
	<u>M. bovis</u> BCG	71kD	PL1-101
		65kD	PL1-105
		19kD	PL1-501
		14kD	PL1-502
25	<u>M. smegmatis</u>	65kD	PL1-206
	<u>M. avium</u>	65kD	PL1-401
	<u>M. africanum</u>	65kD	PL1-301



-23-

For purposes of comparison, genes encoding the following proteins were isolated for M. tuberculosis and M. leprae:

	<u>Mycobacterium</u>	<u>Protein</u>	<u>Clone</u>
05	<u>M. tuberculosis</u>	71kD	Y3272
		65kD	Y3150
		19kD	Y3147
		14kD	Y3248
	<u>M. leprae</u>	65kD	

10 The following strains were used for this purpose:

	<u>Species</u>	<u>Isolate</u>
	<u>M. leprae</u>	Armadillo isolate (WHO)
	<u>M. tuberculosis</u>	Erdmann strain
15	<u>M. africanum</u>	African clinical isolate
	<u>M. bovis</u> BCG	Danish vaccine strain
	<u>M. smegmatis</u>	MC <sup>2</sup> -6
	<u>M. avium</u>	AIDS patient isolate

20 DNA from recombinant lambda gt11 clones was isolated, as described above, and mapped with restriction endonucleases, using standard techniques. Davis, R.W. et al., Advanced Bacterial Genetics: A Manual for Genetic Engineering, Cold Spring Harbor (1980).

25 Figure 4 presents a comparison of the restriction maps for four genes of M. tuberculosis with the restriction maps for four genes of M. bovis BCG which encode proteins of the same molecular weight. As is evident from the figure, in each case, the

-24-

restriction sites on the two genes (e.g., those on the M. tuberculosis gene and those on the M. bovis gene which encodes a protein of the same molecular weight) are essentially identical. This indicates  
05 that the sequence of the genes of the two mycobacteria (at least those encoding these four proteins) are very similar and, therefore, the proteins they encode are also very similar.

Figure 5 presents a comparison of the restriction map for the gene encoding the 65kD protein for  
10 the six mycobacteria. As is evident, the restriction maps for the genes encoding the 65kD protein of M. tuberculosis, M. africanum, M. bovis BCG, M. smegmatis and M. avium are essentially identical.  
15 The fact that there is no detectable difference among these mycobacteria at the level of the restriction map is an indication that, at least at this level, the encoded proteins are the same.

As is also evident, the map of the M. leprae  
20 65kD gene has several identical restriction sites in common with those of the other mycobacteria; it also has two sites not found in the other genes and lacks three sites present in the others. This indicates that, at the level of the restriction map, there are  
25 similarities in the DNA (and the encoded protein). In addition, however, there are differences apparent at this level.

#### IX. Diagnostic, Therapeutic and Preventive Applications

30 The isolation of genes encoding major protein antigens of M. tuberculosis makes it possible to

-25-

address problems which presently exist in diagnosing treating and preventing tuberculosis. Isolation of genes encoding proteins of other mycobacteria, such as M. bovis BCG, M. africanum, M. smegmatis and M. avium makes it possible to address similar problems in diseases which they cause.

The nucleotide sequence of three of the five genes has been determined. The sequence of the remaining genes can be determined using well-known methods, such as that of Sanger et al. Sanger, F. et.al., Proceedings of the National Academy of Sciences, USA, 74:5463-5467 (1977). The amino acid sequence of each of the immunodominant proteins has been deduced from the nucleotide sequence of the three genes and can be done for the others.

Identification and characterization of the genes for major tuberculosis protein antigens and of the proteins themselves make it possible to develop improved reagents for diagnosis and immuno-prophylaxis of tuberculosis. Proteins antigens encoded by an entire gene, or amino acid sequences (e.g., peptides, protein fragments) which make up the antigenic determinant of a M. tuberculosis antigen (i.e., M. tuberculosis-specific antigenic determinants) may be used in serodiagnostic tests and skin tests. Such antigens would be highly specific to the tuberculosis bacillus and the tests in which they are used would also be highly specific. Highly specific serological tests would be of great value in screening populations for

-26-

individuals producing antibodies to M. tuberculosis-specific antigenic determinants; in monitoring the development of active disease in individuals and in assessing the efficacy of treatment. As a result,  
05 early diagnosis of tuberculosis will be feasible, thus making it possible to institute treatment at an early stage of the disease and, in turn, to reduce the likelihood it will be transmitted.

As a result of the work described, it is also  
10 possible to determine which segment(s) of the M. tuberculosis antigen is recognized by M. tuberculosis-specific T cells. A mixture of peptides recognized by helper T cells can serve as a specific skin test antigen useful in assessing  
15 immunological status (delayed hypersensitivity) of infected individuals and those with whom they come in contact. This specific skin test antigen would be useful in evaluating rapidly the immunological efficacy of anti-tuberculosis vaccines.

20 It is reasonable to expect that the products encoded by M. tuberculosis genes, particularly those shown to be recognized by helper T cells, are themselves immunogenic and thus useful components of vaccines against tuberculosis. These products  
25 include proteins and portions of such proteins (e.g., polypeptides and peptides). For example, one approach to vaccine development is the introduction of genes encoding products (e.g., polypeptides) which provide immunological protection into viruses  
30 such as vaccinia virus, or bacteria, such as cultivatable mycobacteria, thus producing a vaccine

-27-

capable of engendering long-lasting and very specific immunity. The genes encoding five immunodominant protein antigens of the tuberculosis bacillus, described herein, are useful for that purpose; genes encoding the 65kD, 19kD and 71kD antigens, or a portion thereof, are particularly valuable in vaccine construction.

Because of the similarities in the DNA encoding similarly-sized proteins and, thus, of the encoded proteins themselves, it is possible that, for example, a vaccine effective against two or more of the mycobacteria can be produced.

#### EXEMPLIFICATION

##### Isolation and Analysis of Recombinants Expressing the 65kD M. tuberculosis Antigen

The recombinant DNA library of M. tuberculosis genomic DNA fragments in the lambda gt11 vector was constructed as described above. Recombinant phage lambda RY3143 and lambda RY3146 were used. Young, R.A. et al., Proceedings of the National Academy of Sciences, USA, 82:2583-2587 (1985). Subclones of the mycobacterial DNA inserts in these recombinant phage were constructed in pUC19 or M13mp9 vectors using standard recombinant DNA techniques. Messing, J. and J. Viera, Gene, 19:269-276 (1982). Maniatis, T. et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1982).

-28-

Monoclonal antibodies specific for the 65kD antigen were obtained from the Immunology of Tuberculosis Scientific Working Group under a grant from the WHO/World Bank/UNDP Special Program for Vaccine Development. These antibodies included IT-13 (WTB-78), IT-31 (SA2D5H4), and IT-33 (MLIIH9). Coates, A.R.M. et al., Lancet, 2:167-169 (1981). Gillis, T.P. and T.M. Buchanon, Immunology, 37:172-178 (1982). Anti-B-galactosidase antibodies were purchased from CooperBiomedical. Polyclonal rabbit antisera directed against a sonicate of M. tuberculosis strain H37Rv were elicited as described by Minden and co-workers. Minden, P. et al., Infect. Immun., 46:519-525 (1984). Results are shown in Table 2.

-29-

TABLE 2: PATTERNS OF ANTIBODY REACTIVITIES<sup>a</sup>

<u>Number of Clones</u>		<u>Reactivity with Antibodies</u>		
		<u>IT-13</u>	<u>IT-31</u>	<u>IT-33</u>
	27	+	+	+
05	1	+	+	+
	2	+	-	+
	3	-	+	+
	1	+	-	-
	2	-	+	-
10	2	-	-	+

<sup>a</sup>: Recombinant clones expressing antigens reactive with the 65kD antigen specific monoclonal antibodies IT-13, IT-31, and IT-33 were isolated as described above. For the initial screen, a pool of the three antibodies was used; it contained a 1:1000 dilution of each antibody to screen a total of about  $8 \times 10^5$  recombinant phage from the lambda gt11-M. tuberculosis library. To determine which monoclonal antibody reacted with which of the 38 plaque-purified recombinants, about 100 pfu of each recombinant phage were inoculated in small spots on a lawn of Y1090. The phage were allowed to grow and induced to synthesize the foreign proteins as described previously. The filters were then reacted with a 1:1000 dilution of one of the monoclonal hybridoma antibodies as described above.

-30-

The lambda gt11-M. tuberculosis library was screened with the monoclonal antibodies specific for the 65kD antigen and clones reactive with them were isolated essentially as described by Young et al.

05 Young, R.A. et al., Proceedings of the National Academy of Sciences, USA, 82:2583-2587 (1985). Briefly, for each 150mm LB plate, 0.6ml of a fresh overnight culture of Y1090 was infected with 1-2  $\times 10^5$  plaque forming units of the library. After

10 3.5-4 hours of growth at 42°C, the plaques were overlaid with a dry nitrocellulose filter which had been saturated with 10mM isopropyl-B-D-thiogalactopyranoside (IPTG). The plates were incubated an

15 additional 3.5-4 hours at 37°C and then removed to room temperature and the position of the filters marked. The filters were washed briefly in TBST (50 mM Tris-HCl, pH 8, 150mM NaCl, 0.05% Tween 20) and then incubated in TBST + 20% fetal calf serum.

20 After 30 minutes at room temperature, the filters were transferred to TBST plus antibody. For the initial screen, the antibody mix contained a 1:1000 dilution of IT-13, IT-31, and IT-33. The filters were incubated with the antibody solution overnight at 4°C with gentle agitation, washed in TBST and

25 reacted with biotinylated goat anti-mouse immunoglobulin, the Vectastain ABC reagent, and developer as described by the manufacturer (Vector Laboratories). After the color had developed the filters were washed with several changes of water

30 and air dried. Phage corresponding to positive signals were twice plaque purified. To determine



-31-

which monoclonal antibodies reacted with which of the recombinant phage, about 100 pfu of a purified phage stock were inoculated in a small spot on a lawn of Y1090 bacteria on an LB plate. The phage  
05 were allowed to grow and induced to synthesize the foreign proteins as described above. The filters were then reacted with a 1:1000 dilution of one of the monoclonal antibodies. The subsequent steps were the same as for the initial screen.

10 Western blot assays were carried out as follows: Cells containing phage or plasmids in which the expression of the foreign sequences was under the control of the E. coli lac gene regulatory sequences were induced to synthesize the foreign  
15 proteins by incubating the cells in the presence of 2.5mM IPTG for 2 hours. Crude lysates of cells expressing lambda gt11 recombinants were made as described in Huynh et al. Huynh, T.V. et al., In: DNA Cloning Techniques: A Practical Approach, (D.  
20 Glover, ed.) IRL Press, Oxford, Vol. 1, pp. 49-78 (1985). Crude lysates of cells expressing plasmid encoded proteins were made by harvesting cells from overnight cultures and resuspending the cells in 10 mM Tris pH7.5/10 mM EDTA containing 100 ug  
25 lysozyme/ml. After 10 minutes at room temperature, SDS was added to a final concentration of 0.5%. A protease inhibitor (Trasylol, Boehringer Mannheim) was added to all crude lysates at a final concentration of 0.3%. The crude protein preparations  
30 were electrophoresed on 10% polyacrylamide-SDS Laemmli gels and the separate proteins electrophor-

-32-

etically transferred to nitrocellulose. Laemmli, U.K., Nature, 227:680-685 (1970). Towbin, H. et al., Proceedings of the National Academy of Sciences, USA, 76:4350-4354 (1979). The immobilized  
05 proteins were reacted with a 1:1000 dilution of monoclonal antibody IT-13 in TBST overnight at 4°C. The nitrocellulose filters were then washed, reacted with peroxidase-conjugated goat anti-mouse immuno-  
globulin, and developed as described by Niman and  
10 co-workers. Niman, H.L. et al., Proceedings of the National Academy of Sciences, USA, 80:4949-4953 (1983).

The sequences of 5'-end-labeled restriction fragments of the mycobacterial DNA were determined  
15 by a modification of the partial chemical degradation technique of Maxam and Gilbert. Brow, M.A.D. et al., Mol. Biol. Evol., 2:1-12 (1985). Maxam, A.M. and W. Gilbert, Proceedings of the National Academy of Sciences, USA, 74:560-564  
20 (1976). For the M13/dideoxy sequencing studies, Sau3AI fragments from the mycobacterial DNA inserts were subcloned into the BamHI site of M13mp9. Phage DNA was isolated from the M13 recombinants and subjected to the dideoxy chain termination  
25 sequencing reactions. Biggin, M.D. et al., Proceedings of the National Academy of Sciences, USA, 80:3963-3965 (1983). Sanger, F. et al., Journal of Molecular Biology, 143:161-178 (1980). The products of the sequencing reactions were  
30 electrophoresed on 6% acrylamide/7M urea/0.5-2.5 x TBE gradient sequencing gels. The gels were dried

-33-

under vacuum and exposed to Kodak XRP-1 film. The nucleotide sequences were determined independently for both strands of the mycobacterial DNA.

05 Computer-aided analyses of the nucleic acid sequences and deduced protein sequences were performed using the Databases and programs provided by the Nucleic Acid and Protein Identification Resources of the National Institutes of Health as well as the programs of Chou and Fasman and Hopp and  
10 Woods. Chou, P.Y. and G.D. Fasman, Adv. Enzym., 47:45-148 (1978). Hopp, T.P. and K.P. Woods, Proceedings of the National Academy of Sciences, USA, 78:3824-3828 (1981). The nucleotide sequence of the region containing the M. tuberculosis 65kD  
15 gene and the deduced amino acid sequence of the two long open reading frames are represented in Figure 8.

B-galactosidase assays were also carried out. Cells were grown in LB broth or LB broth plus 2.5mM  
20 IPTG to an OD<sub>600</sub> of about 0.3. Crude lysates were made and b-galactosidase activity assayed as described by Miller. Miller, J.H., Experiments in Molecular Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1972).

### 25 Equivalents

Those skilled in the art will recognize or be able to ascertain, using no more than routine experimentation, many equivalents to the specific materials and components described herein. Such  
30 equivalents are intended to be encompassed in the scope of the following claims.

-34-

CLAIMS

1. Isolated DNA encoding an immunogenic protein antigen of Mycobacterium tuberculosis.
- 05 2. DNA of Claim 1 selected from the group consisting of DNA encoding Mycobacterium tuberculosis protein antigens of molecular weight 71kD, 65kD, 19kD, 14kD and 12kD.
- 10 3. Isolated DNA encoding an immunodominant protein antigen of Mycobacterium tuberculosis, the protein antigen having a molecular weight of approximately 65kD and recognized by a monoclonal antibody selected from the group consisting of: IT-31; C1.1; IIH9; IIC8; T2.3; Y1-2; SA2.D7C and IT-13.
- 15 4. Isolated DNA encoding an immunodominant protein antigen of Mycobacterium tuberculosis, the protein antigen having a molecular weight of approximately 19kD and recognized by a monoclonal antibody selected from the group consisting of: IT-10; IT-12; IT-16; and IT-19.
- 20 5. Isolated DNA encoding an immunodominant protein antigen of Mycobacterium tuberculosis, the protein antigen having a molecular weight of approximately 71kD and recognized by the monoclonal antibody IT-11.
- 25

-35-

6. Isolated DNA encoding an antigenic determinant of Mycobacterium tuberculosis protein.
7. DNA of Claim 6 which encodes an antigenic determinant selected from the group consisting of antigenic determinants of Mycobacterium tuberculosis proteins of molecular weight 71kD, 65kD, 19kD, 14kD and 12kD.
8. Isolated DNA encoding an amino acid sequence of an antigenic determinant of Mycobacterium tuberculosis protein, said protein having a molecular weight of approximately 65kD.
9. Isolated Mycobacterium tuberculosis DNA encoding an immunodominant protein antigen having a molecular weight of approximately 65kD, said DNA selected from the group consisting of:
  - a. the DNA insert of clone Y3141;
  - b. the DNA insert of clone Y3143;
  - c. the DNA insert of clone Y3150;
  - d. the DNA insert of clone Y3253; and
  - e. the DNA insert of clone Y3262.
10. A protein antigen encoded by DNA of Claim 9.
11. A protein antigen of Claim 10, wherein the protein antigen is recognized by a monoclonal antibody selected from the group consisting of IT-31; C1.1; IIH9; IIC8; T2.3; Y1-2; SA2.D7C and IT-13.

-36-

- 05 12. Isolated DNA having a nucleotide sequence selected from the group consisting of: a) the nucleotide sequence represented in Figure 6, or a portion thereof; b) the nucleotide sequence represented in Figure 7, or a portion thereof; and c) the nucleotide sequence represented in Figure 8, or a portion thereof.
- 10 13. A protein or a peptide selected from the group consisting of: a) proteins or peptides encoded by the nucleotide sequence represented in Figure 6, or a portion thereof; b) proteins or peptides encoded by the nucleotide sequence represented in Figure 7, or a portion thereof; and c) proteins or peptides encoded by the nucleotide sequence represented in Figure 8, or a portion thereof.
- 15 14. A peptide having the amino acid sequence of an antigenic determinant of Mycobacterium tuberculosis protein, said antigenic determinant being unique to Mycobacterium tuberculosis protein.
- 20 15. A peptide encoded by isolated Mycobacterium tuberculosis DNA, said peptide recognized by helper T cells.
- 25 16. A peptide encoded by the Mycobacterium tuberculosis DNA insert of clone Y3150 or a portion of said DNA insert.

-37-

17. Isolated DNA encoding a protein of Myco-  
bacterium africanum the protein having a  
molecular weight of 65kD.
- 05 18. Isolated DNA encoding a protein of Myco-  
bacterium avium, the protein having a molecular  
weight of 65kD.
19. A vaccine comprising DNA encoding Mycobacterium  
tuberculosis protein in a recombinant vaccine  
vector capable of expressing said DNA.
- 10 20. A vaccine of Claim 19 in which the recombinant  
vaccine vector is vaccinia virus or cultivat-  
able mycobacteria.
- 15 21. A vaccine of Claim 20 in which the DNA encodes  
the 65kD Mycobacterium tuberculosis protein  
recognized by the monoclonal antibody IT-13, or  
a portion of said protein.
22. A vaccine comprising DNA encoding an antigenic  
determinant unique to Mycobacterium tubercu-  
losis cultivatable mycobacteria capable of  
20 expressing said DNA.
23. A method of detecting antibody against Myco-  
bacterium tuberculosis in a biological fluid,  
comprising the steps of:
- 25 a) incubating an immunoadsorbent com-  
prising a solid phase to which is attached

-38-

immunodeterminant Mycobacterium tuberculosis protein with a sample of the biological fluid to be tested, under conditions which allow the anti-Mycobacterium tuberculosis antibody in the sample to bind to the immunoabsorbent;

05

b) separating the immunoabsorbent from the sample; and

10

c) determining if antibody is bound to the immunoabsorbent, as an indication of anti-Mycobacterium tuberculosis in the sample.

24. A method of Claim 23 in which the Mycobacterium tuberculosis protein attached to the solid phase has a molecular weight of approximately 65kD.

15

25. A method of detecting antibody against Myco-bacterium tuberculosis in a biological fluid, comprising the steps of:

20

a) incubating an immunoabsorbent comprising a solid phase to which is attached a peptide having the amino acid sequence of an antigenic determinant of Mycobacterium tuberculosis protein with a sample of the biological fluid to be tested, under conditions which allow antibody against Mycobacterium tuberculosis to bind to the immunoabsorbent;

25

b) separating the immunoabsorbent; and  
c) determining if antibody is bound to the immunoabsorbent, as an indication of the



-39-

presence of the antibody against Mycobacterium tuberculosis in the sample.


- 05 26. A method of Claim 25 in which the peptide has the amino acid sequence of an antigenic determinant which is unique to Mycobacterium tuberculosis protein.
- 10 27. A kit useful in detecting antibody against Mycobacterium tuberculosis in a biological fluid, comprising a collection of reagents for immunoassay of said antibody, said collection of reagents a solid phase to which is attached immunodeterminant Mycobacterium tuberculosis protein or a peptide having the amino acid sequence of an antigenic determinant of
- 15 Mycobacterium tuberculosis.

1/43


FIGURE 1

1Kb


12K



14K



19K




2/43


FIGURE 1 (Cont'd)

1Kb

65K




71K




3/43

FIG.2



4/43  
FIG.3









FIGURE 4



6/43

FIGURE 4 (Cont'd)



7/43




FIG. 5



8/43

FIGURE 6

```

F R V N R L G E I A R P G A R I A H Q G
S V S I A S V R * P D Q A R G S R T K A
P C Q S P R * D S P T R R A D R A P R R
TTCCGTGTCATCGCCTCGGTGAGATAGCCCGACGAGCGCGGATCGCGCACCAAGC
10      20      30      40      50      60
AAGGCACAGTTAGGGAGCCACTCTATCGGGCTGGTCCGCGCCCTAGCGCGTGTCCG
E T D I A E T L Y G S W A R P D R V L A
G H * D G R H S L G V L R A S R A G; L R
R T L R R P S I A R G P A R I A C W P A

A A Q G Q Q V V Q V M R G V F G H A Q R
P R R V S R L C R L C V A F S A M H N A
R A G S A G C A G Y A W R F R P C T T R
GCCGCGCAGGTCAGCAGGTGTGTCAGGTTATGCGTGGCGTTTCGGCCATGCACAACGC
70      80      90      100      110      120
CGGCGGTCCTCCAGTCCTCAACACGTCCTCAATACGCACCGCAAAGCCGGTACGTGTGCG
G R L T L L N H L N H T A N E A M C L A
R A P D A P Q A P * A H R K R G H V V R
A C P * C T T C T I R P T K P W A C R A

```

FIGURE 6 (CONT'D)

A E A R E I E V H L R R G L G A R G H L  
 R K R G K \* K C I S A G A S V P G A I W  
 G S A G N R S A S P Q G P R C P G P S G  
 GCGAAGCGGGAAATAGAGTGCATCTCCGCAGGGGCTCGGTGCCCGGGGCCATCTG  
 130 140 150 160 170 180  
 CGCCTTCGGCCCTTTATCTTACGTAGAGCGTCCCCGGAGCCACGGCCCCGGTAGAC  
 R F R P F Y F H M E A P A E T G P A M Q  
 P L A P F L L A D G C P G R H G P G D P  
 S A R S I S T C R R L P R P A R P W R S  
 9/43  
 E L D L H P V D G V G L P G L G D V D R  
 N S I S T P S M V W V S P V S V M S T V  
 T R S P P R R W C G S P R S R \* C R P S  
 GAACTCGATCTCACCCCGTCGATGGTGGTCTCCCCGGTCTCGGTGATGTCGACCGT  
 190 200 210 220 230 240  
 CTTGAGCTAGAGGTGGGCAGCTACCAACAGAGGGGCCAGAGCCACTACAGCTGGCA  
 F E I E V G D I T H T E G T E T I D V T  
 V R D G G R R H H P D G R D R H H R G D  
 S S R W G T S F T P R G P R P S T S R R

FIGURE 6 (CONT'D)

R H D E R N L T G R Q C L P E A A A D V  
 G T T S E T S P V D S V C P R P Q P T C  
 A R R A K P H R S T V S A R G R S R R A  
 CGCAGCAGCGGAAACCTCACC GGTCGACAGTGTCTGCCCGAGCGCGCAGCGCGTG  
 250 260 270 280 290 300  
 GCCGTGCTCGCTTTGGAGTGGCCAGCTGTACACAGCGGCTCCGGCGTGGCTGCAC  
 P V V L S V E G T S L T Q G L G C G V H  
 A R R A F G \* R D V T D A R P R L R; R A  
 C S S R F R V P R C H R G S A A A S T G

10/43

P P E T A R Q H G A V H V A R T A H H R  
 P R R P R A N T V P Y M \* P A R R I I A  
 P G D R A P T R C R T C S P H G A S S P  
 CCCCCGAGACCGCGGCCAACACGGTGCCGTACATGTAGCCCGCAGCGGCATCATCGC  
 310 320 330 340 350 360  
 GGGGGCCTCTGGCGCGGTTGTGCCACGGCATGTACATCGGGCGTCCCGGTAGTAGCG  
 G R L G R A L V T G Y M Y G A R R M M A,  
 G P S R A G V R H R V H L G C P A D D G  
 G S V A R W C P A T C T A R V A C \* R R

FIGURE 6 (CONT'D)

R A G V D V F L H G V R G E P L R R Q H  
 E P A \* M F S C T A C A V N P S G A S T  
 S R R R C F P A R R A R \* T P P A P A P  
 CGAGCCGGCTAGATGTTTCCTGCACGGCGTGCGGGTGAACCCCTCCGGCGCCAGCAC  
 370 380 390 400 410 420  
 GCTCGCCGCATCTACAAAGGACGTGCCGCACGCCCACTTGGGAGGCCCGGTCGTG  
 S G A Y I N E Q V A H A T F G E P A L V  
 L R R L H K G A R R A R H V G G A G A G  
 A P T S T K R C P T R P S G R R R W C R  
 11/43  
 R H L S R V H V G L G G D A E H P T E M  
 A T F P A S T S A W V V T P S T P P K \*  
 P P F P R P R P G W \* R R A P H R N D  
 CGCCACCTTTCGGCGTCCACGTCGGCTGGTGGTGACGCCGAGCACCCACCGAAATG  
 430 440 450 460 470 480  
 GCGGTGGAAGGCGCAGGTGCAGCCGACCCACCACTGCGGCTCGTGGGGTGGCTTAC  
 A V K G A D V D A Q T T V G L V G G F H  
 G G K G R G R R G P H H R R A G W R F S  
 W R E R T W T P R P P S A S C G V S I I

FIGURE 6 (CONT'D)

I D M A V G V D D R D H G A V G S A V G  
 S T W L W V \* M T A T T G R S A P R W A  
 R H G C G C R \* P R P R G G R L R G G R  
 ATC G A T G G C T G T G T A G A C C G C C A C C G G G G T C G G T C C G C G G T G G G C  
 490 500 510 520 530 540  
 T A G C T G T A C C G A C C A C A T C T A C T G G C G T G T G C C C G C C A G C C A G G C G C C A C C G  
 D V H S H T Y I V A V V P R D A G R H A  
 R C P Q P H L H G R G R P P R S R P P R  
 S M A T P T S S R S W P A T P E A T P A  
 12/43  
 A I Q V Q R G G G H L G G H Q R V D D D  
 R Y K S S A A A A T S V D T N G S M T I  
 D T S P A R R R P P R W T P T G R \* R S  
 G G A T A C A A G T C C A G C G C G C G C C C C C T C G G T G G A C A C C A C G G T C G A T G A C G A T  
 550 560 570 580 590 600  
 C G C T A T G T T C A G G T C G C G C C G C C G G T G G A G C C A C C T G T G T T G C C C A G C T A C T G C T A  
 R Y L D L A A A A A V E T S V L P D I V I  
 S V L G A R R R G G R H V G V P R H R D  
 I C T W R P P P W R P P C W R T S S S \*

FIGURE 6 (CONT'D)

Q P S V T L N E A D I G D I E S A D L I  
 S P V S P S T K L I L E I S N P R T \* \*  
 A Q C H P Q R S \* Y W R Y R I R G P D R  
 CAGCCAGTGTCAACGAAGCTGATATTGGAGATATCGAATCCGCGACCTGATA  
 610 620 630 640 650 660  
 GTCGGGTACAGTGGGAGTTGCTTCGACTATAACCTCTATAGCTTAGCGCCTGGACTAT  
 L G T D G E V F S I N S I D F G R V Q Y  
 A W H \* G \* R L Q Y Q L Y R I R P G S L  
 G L T V R L S A S I P S I S D A S R I S  
 13/43  
 D A R H H L V E A L F R G Q L G L P P Q  
 M P G T T W \* R P C F A V S W D C R H R  
 C P A P P G R G P V S R S A G I A A T G  
 GATGCCCGCACCACTGGTAGAGGCCCTGTTTCGCGGTGAGTGGGATTGCCGCCACAG  
 670 680 690 700 710 720  
 CTACGGGCGGTGGACCATCTCCGGGACAAAGCGCCAGTCGACCCCTAACGGCGGTGTC  
 I G P V V Q Y L G Q K A T L Q S Q R W L  
 H G A G G P L P G T E R D A P I A A V P

FIGURE 6 (CONT'D)

A R C W R T S A R N R P \* S P N G G C A  
 A G M H R C R R G T V E K R V R V V P  
 L G C T D V G A A P S R N E Y A S L S H  
 W D A P M S A R H R R E T S T R R C P T  
 GCTGGATGCCCGATGTCGGCGCGCACCGTCGAGAAACGAGTACGCGTGTGTCCCA  
 730 740 750 760 770 780  
 CGACCCCTACGTGGCTACAGCCGCGCGTGGCAGCTCTTGTCTCATGCGCAGCAACAGGGT  
 S P H V S T P A A G D L F S Y A D N D W  
 Q S A G I D A R C R R S V L V R R Q G V  
 P I C R H R R P V T S F R T R T T G C<sup>14/43</sup>  
 H H A T I G S L D H T R G Q R G N E S A  
 T T R P S A A L I T H G D S A A M N P R  
 P R D H R Q P \* S H T G T A R Q \* I R D  
 CACCACGACCATCGGCAGCCTTGATCACACACGGGACAGCGCGCAATGAATCCGCG  
 790 800 810 820 830 840  
 GTGGTGGCTGTAGCCGTGGAAGTGTGTGCCCCCTGTGCGCGCTACTAGGCGC  
 V V R G D A A K I V C P S L A A I F G R  
 G R S W R C G Q D C V P V A R C H I R S  
 W A V M P L R S \* V R P C R P L S D A I

FIGURE 6 (CONT'D)

I G V V E I R C V M Q R \* R V F T V C R  
 S A S S K S V V S C N G N E C S P C A A  
 R R R R N P L C H A T V T S V H R V P P  
 ATCGGCGTCGAAATCCGTTGTGTCATGCAACGGTAACGAGTGTTCACCGTGTGCCG  
 850 860 870 880 890 900  
 TAGCCGACGAGCTTAGGCAACACAGTACGTGTCATTGCTCACAAGTGGCACACGGCG  
 D A D D F D T T D H L P L S H E G H A A  
 R R R R F G N H \* A V T V L T \* R T G G  
 P T T S I R Q T M C R Y R T N V T H R R  
 15/43  
 L D D G S G R F V F H R H Y I A T T V  
 W M T A V G G L C S I G T T L P L L R C  
 G \* R Q W E V C V P S A L H C H Y Y G A  
 CTGGATGACGGCAGTGGGAGGTTTGTGTTCCATCGGCACTACATGCCACTACTACGGTG  
 910 920 930 940 950 960  
 GACCTACTGCCGTCAACCTCCAAACACAAAGTAGCCGTGATGTAACGGTGATGATGCCAC  
 Q I V A T P P K H E M P V V N G S S R H  
 P H R C H S T Q T G D A S C Q W \* \* P A  
 S S P L P L N T N W R C \* M A V V V T C



FIGURE 6 (CONT'D)

H A G R C R W R T T L P T R K R E F S A  
 T P V D A V G E P R Y R P E R E N F P P  
 R R \* M P L A N H A T D Q K E R I F R R  
 CACGCCGTAGATGCCGTGGCGAACCCAGCTACCGACCAGAAAGAGAGAATTTCCGCC  
 970 980 990 1000 1010 1020  
 GTGCGGCATCTACGGCAACCGCTTGGTGGATGGCTTCTCTCTTAAAGGCGG  
 V G T S A T P S G R \* R G S L S F K G G  
 R R Y I G N A F W A V S W F S L I K R R  
 A P L H R Q R V V S G V L F L S N E A A  
 16/43  
 A P R P R A L L T R I L P K R S S M P M  
 H L D L G P C \* R A Y C R S G P Q C R W  
 T \* T S G P A N A H T A E A V L N A D G  
 GCACCTAGACCTCGGGCCCTGCTAACGGCGCATACTGCCGAGCGGTCTCAATGCCGATG  
 1030 1040 1050 1060 1070 1080  
 CGTGGATCTGAGCCCGGACGATTGCGCGTATGACGGCTTCGCCAGGAGTTACGGCTAC  
 C R S R P G Q \* R A Y Q R L P G \* H R H

17/43

FIGURE 6 (CONT'D)

V \* V E P G A L A C V A S A T R L A S P  
G L G R A R S V R M S G F R D E I G I S

D R Y D R Q R S T G \* S V D \* R S R \* P  
T A T T G K G A Q G E A W T D G R G S R  
P L R Q A K E H R  $\sqrt{V}$  K R G L T V A V A G  
GACCGTACGACAGGCAAGGAGCACAGGGTGAAGCGTGGACTGACGGTCGCGGTAGCCG

1090 1100 1110 1120 1130 1140

CTGGCGATGCTGCCGTTTCCTCGTGTCCTCCACTTCGCACCTGACTGCCAGCGCCATCGGC

V A V V P L P A C P S A H V S P R P L R  
G S R C A F S C L T F R P S V T A T A P  
R \* S L C L L V P H L T S Q R D R Y G S

E P P F W S Q V F P D V Q A T S R L Q E  
S R H S G R R S F R M F K Q Q V D Y R K  
A A I L V A G L S G C S S N K S T T G S  
GAGCCGCCATTCTGGTCGAGGTCTTCCGGATGTTCAAGCAACAAGTCGACTACAGGAA

1150 1160 1170 1180 1190 1200

CTCGGCGTAAGACCAGCGTCCAGAAGCCCTACAAGTTCGTTGTTTCAGCTGATGCCCTT

L R W E P R L D K R I N L C C T S \* L F  
A A M R T A P R E P H E L L L D V V P L  
C C N C D C T K G S T \* A V L R S C S A

FIGURE 6 (CONT'D)

A V R P R P R Q A R R Q A P A P P P G R  
 R \* D H D R G R H D G K P R R R L R A E  
 G E T T A A G T T A S P G A A S G P K  
 GCGTGAGACCGACCGCGCAGGACGACGCAAGCCCGCGCCCTCCGGGCCGA  
 1210 1220 1230 1240 1250 1260  
 CGCCACTCTGTGCGCGCGTCCGTGCTGCCGTTCGGGGCGCGGAGGCCGGCT  
 R H S W S R P L C S P L G R R R R' A S  
 P S V V V A A P V V A L G P A A E P G F  
 T L G R G R C A R R C A G A G G P R L  
 18/43  
 R S S S T V R T R T S P A P W C A Q P R  
 G R H R R \* G P E R H R L R G V H N R G  
 V V I D G K D Q N V T G S V V C T T A A  
 AGGTCGTCACGGTAAGGACCAAGACGTCACCGGCTCCGTGGTGTGCACAACCGCGG  
 1270 1280 1290 1300 1310 1320  
 TCCAGCAGTAGTGCCATTCCCTGGTCTTGCAAGTGGCCGAGGCACACACGTGTGGCGCC  
 P R \* R R Y P G S R \* R S R P T C L R P  
 T T M S P L S W F T V P E T T H V V A A  
 D D D V T L V L V D G A G H H A C G R G

FIGURE 6 (CONT'D)

P A M S T S R S A G R R P A L P P C S P  
 R Q C Q H R D R R G G D R H C R R A H R  
 G N V N I A I G G A A T G I A A V L T D  
 CCGGCAATGTCAACATCGCGATCGCGGGGGGCGGACCGGCATGCGCGCGTGCTCACCG  
 1330 1340 1350 1360 1370 1380  
 GGCCGTTACAGTTGTAGCGCTAGCCGCCCGCCGCTGGCCGTAACGGCGGCACGAGTGGC  
 R C H \* C R S R R P P S R C Q R R A \* R  
 P L T L M A I P P A A V P M A A T S V S  
 A I D V D R D A P R R G A N G G H E G V  
 19/43  
 T A T L R R \* S P L G S V T S T A S R W  
 R Q P S G G E V R W A R \* R Q R R H A G  
 G N P P E V K S V G L G N V N G V T L G  
 ACGGCAACCCTCCGGAGGTGAAGTCCGTTGGGCTCGGTAACGTCAACGGCGTCACGCTGG  
 1390 1400 1410 1420 1430 1440  
 TGCCGTTGGAGGCCCTCCACTTCAGGCAACCCGAGCCATTGCAGTTGCCCGCAGTGCGGACC  
 R C G E P P S T R Q A R Y R \* R R \* A P  
 P L G G S T F D T P S P L T L P T V S P  
 A V R R L H L G N P E T V D V A D R Q S

FIGURE 6 (CONT'D)

D T R R A P D R V T P R Q P R T A A T T  
 I H V G H R T G \* R L G N Q G R Q P L Q  
 Y T S G T G Q G N A S A T K D G S H Y K  
 GATACGTCGGGCACCGGTAACGCCCTCGGCAACCAAGGACGGCAGCCACTACA  
 1450 1460 1470 1480 1490 1500  
 CTATGTGACCCCGTGGCCTGTCCCATGCGGAGCCGTTGGTTCCTGCCGTCGGTGATGT  
 I C T P C R V P Y R R P L W P R C G' S C  
 Y V D P V P C P L A E A V L S P L W \* L  
 V R R A G S L T V G R C G L V A A V V L  
 20/43  
 R S L G P L P G S T W P T R C H R \* T S  
 D H W D R Y R G R H G Q P D V T G E Q V  
 I T G T A T G V D M A N P M S P V N K S  
 AGATCACTGGGACCGCTACCGGGGTCGACATGGCCCAACCCGATGTCACCGGTGAACAAGT  
 1510 1520 1530 1540 1550 1560  
 TCTAGTGACCCCTGGCGATGGCCCCCAGCTGTACCGGTTGGGCTACAGTGCCACTTGTCA  
 S \* Q S R \* R P R C P W G S T V P S C T  
 I V P V A V P T S M A L G I D G T F L D  
 D S P G S G P D V H G V R H \* R H V L R

FIGURE 6 (CONT'D)

R S K S R \* P V P N L K R V D A G C E Q  
 V R N R G D L F L T \* S V S M R A V N S  
 F E I E V T C S ] \* P K A C R C G L \* T A  
 CGTTCGAAATCGAGGTGACCTGTTCTTAACCTAAAGCGTGTGATCGGGGTGTGAACAG  
 1570 1580 1590 1600 1610 1620  
 GCAAGCTTAGCTCCACTGGACAAGGATTGGATTTCGCACAGCTACGCCCGACACTGTC  
 T R F R P S R N R V \* L T D I R A T; F L  
 N S I S T V Q E \* G L A H R H P S H V A  
 E F D L H G T G L R F R T S A P Q S C R  
 21/43  
 R V G A G Q S G L A R R R F E R L P S V  
 A S E P G S Q A \* R G D D S S G C H P S  
 R R S R A V R P S A A T I R A V A I R Q  
 CGGTCGGAGCCGGCAGTCAGGCCCTAGCCGGCGGACGATTTCGAGCGGTGCGCATCCGTC  
 1630 1640 1650 1660 1670 1680  
 GCGCAGCCTCGGCCGTCAGTCCGGATCGCGCGCTGCTAAGCTCGCCAACGGTAGGCAG  
 A D S G P L \* A \* R P S S E L P Q W G D  
 R R L R A T L G L A A V I R A T A M R \*  
 T P A P C D P R A R R R N S R N G D T L

FIGURE 6 (CONT'D)

K W Q P H R K L G I S G \* A T H G D R S  
 S G N R T A N S V Y P G E L L T V I V P  
 V A T A P Q T R Y I R V S Y S R \* S F F  
 AAGTGCAACCGCACCGCAAACTCGGTATATCCGGTGAGCTACTCACGGTGATCGTTCC  
 1690 1700 1710 1720 1730 1740  
 TTCACCGTTGGCGTGTGAGCCATATAGGCCCACTCGATGAGTGCCACTAGCAAGG  
 L P L R V A F E T Y G P S S S V T I T G  
 T A V A G C V R Y I R T L \* E R H D N R  
 H C G C R L S P I D P H A V \* P S' R E T  
 22/43  
 V V R L D H S G D D R Q A E P G A T G L  
 L C A L T T A E T I A R P S P V L P A W  
 C A P \* P Q R R R S P G R A R C Y R L G  
 GTTGCGCCTTGACCAACGCGGAGACGATCGCCAGGCCGAGCCCGGTGCTACCGGCTTG  
 1750 1760 1770 1780 1790 1800  
 CAACACGGGAACGTGGTGCCTCTGTAGCGGTCCGGCTCGGCCACGATGGCCGAAC  
 N H A K V V A S V I A L G L G T S G A Q  
 Q A G Q G C R L R D G P R A R H \* R S' P  
 T R R S W L P S S R W A S G P A V P K A

FIGURE 6 (CONT'D)

A G P \* R I A A G E P L E N L G L Q R G  
 R D R D V S P R A N R S K T S D C S A A  
 G T V T Y R R G R T A R K P R T A A R P  
 GCGGACCGTGACGTATCGCCCGGGCGGAACCGCTCGAAACCTCGGACTGCAGCGCGG  
 1810 1820 1830 1840 1850 1860  
 CGCCCTGGCACTGCATAGCGGCGCCGCTTGGCGAGCTTTGGAGCCTGACGTGCGCGCG  
 R S R S T D G R A F R E F V E S Q L A A  
 P V T V Y R R P R V A R F G R V A A R G  
 P G H R I A A P S G S S F R P S C R P R  
 23/43  
 R N T R P I V D H L Q H D V R R P G A Q  
 G I P G P L S I T C S T T C V G P V L K  
 E Y P A H C R S P A A R R A S A R C S S  
 CGGAATACCGGCCCATTTGTCGATCACCTGCAGCACGACGTGCGTGGCCCGGTGCTCAA  
 1870 1880 1890 1900 1910 1920  
 GCCTTATGGCGCGGTAAACAGCTAGTGGACGTGCTGCAGCAGCGCGGCCACGAGTT  
 P I G P G N D I V Q L V V H T P G T S L  
 S Y G A W Q R D G A A R R A D A R H E L  
 F V R G M T S \* R C C S T R R G P A \* A



FIGURE 6 (CONT'D)

A R R H D R A G T G V H A G V G Q Q V G  
 R V V T I V P G P V C T R A L A S R L V  
 A S S R S C R D R C A R G R W P A G W S  
 GCGCGTCGATCGTGCCGGGACCGGTGTGCACGCGGGCGTTGGCCAGCAGGTGGT  
 1930 1940 1950 1960 1970 1980

CGCGCAGCAGTGTAGCAGGCCCTGGCCACACGTGGCCCGCAACCGTGTCTCAACCA

R T T V I T G P G T H V R A N A L L' N T

A D D R D H R S R H A R P R Q G A P Q D

R R \* S R A P V P T C A P T P W C T P \*

24/43

H H L V Q P C R I T R D D H R F G G Q V

T T W C N R A A S P G M T T G S G G R S

P P G A T V P H H P G \* P P V R G A G R

CACCACCTGGTGCAACCGTGCCGCATCACCCGGGATGACCACCGGTTCGGGGGCGAGTC

1990 2000 2010 2020 2030 2040

GTGGTGACCAACGTTGGCAGCGCGTAGTGGGCCCTACTGTGGCCAGCCCCCGTCCAG

V V Q H L R A A D G P I V V P E P L D

G G P A V T G C \* G P H G G T R P A P R

W R T C G H R M V R S S W R N P P C T S

FIGURE 6 (CONT'D)

E R P L V I W S G N M S V A D R V N R K  
 S A H W \* S G P A T \* A S L T A S T A S  
 A P T G D L V R Q H E R R \* P R Q P Q A  
 GAGCGCCACTGGTGATCTGTCCGGCAACATGAGCGTCGCTGACCCGCGTCAACCGCAAG

2050      2060      2070      2080      2090      2100

CTCGGGGTGACCACTAGACCAGGCCGTTGTACTCGCAGCGGACTGGCGCAGTTGGCGTTC  
 L A W Q H D P G A V H A D S V A D V A L  
 A G V P S R T R C C S R R Q G R \* ' G C A  
 R G S T I Q D P L M L T A S R T L R L G

25/43

P R H V H R S A F Q R P P R V Q T R Q Q  
 R D M S T G P R S S G R P E S R R A S S  
 A T C P P V R V P A A A P S P D A P A A  
 CCGCGACATGTCCACCGGTCCGGTTCACGGCGGCCCGCCGAGTCCAGACGCGCCAGCAG

2110      2120      2130      2140      2150      2160

GCGCTGTACAGGTGGCCAGGCGCAAGTCCCGCGGGGCTCAGGTCTGCGCGTCTC  
 R S M D V P G R E L P R G S D L R A L L  
 A V H G G T R T G A A A G L G S A G A A  
 R C T W R D A N W R G G R T W V R W C C

FIGURE 6 (CONT'D)

Q Q V L D E T C Y P L G L R C H P A H R  
 S R S S T R R V I R S V S D A T R L I A  
 A G P R R D V L S A R S P M P P G S S R  
 CAGCAGGTCCTCGACGAGACGTGTATCCGCTCGGTCTCCGATGCCACCCGGCTCATCGC  
 2170 2180 2190 2200 2210 2220  
 GTCGTCCAGGAGCTGCTCTGCACAATAGCGCAGCCAGAGGCTACGGTGGGCCGAGTAGCG  
 L L D E V L R T I R E T E S A V R S M A  
 A P G R R S T N D A R D G I G G P E D R  
 C T R S S V H \* G S P R R H W G A \* R T  
 26/43  
 V C D G L G I V P Y P L R Q F R V T T D  
 C A T A S G S S P I R C V N S V \* P R I  
 V R R P R D R P L S A A S I P C N H G S  
 GTGTGCGACGGCCTCGGGATCGTCCCCCTATCCGCTGCGTCAATCCGTGTAACACGGAT  
 2230 2240 2250 2260 2270 2280  
 CACACGCTGCCGAGCCCTAGCAGGGGATAGCGGACCGCAGTTAAGGCACATTGGTGCCCTA  
 H A V A E P D D G I R Q T L E T Y G R I  
 T R R G R S R G R D A A D I G H L W P D  
 H S P R P I T G \* G S R \* N R T V V S R

FIGURE 6 (CONT'D)

R R K G S S Q F M T G I G N E L A H T G  
 A A R G V R S S \* L A S A T N W R T R V  
 P Q G E F A V H D W H R Q R T G A H G F  
 CGCCGAAGGGAGTTCGCA GTTCATGACTGGCATCGGCAACGAACTGGCGCACACGGGT

2290 2300 2310 2320 2330 2340

GCGGCGTTCCTCAAGCGTCAAGTACTGACCGTAGCCGTGTGCTTGACCGCGTGTGCCCA  
 A A L P T R L E H S A D A V F Q R V R T  
 G C P S N A T \* S Q C R C R V P A C P N  
 R L P L E C N M V P M P L S S A C V P K

27/43

F T G L P R R Q C G S D V V E H P V E R  
 S L A C R A D S A A A M W S S I R L S A  
 H W P A A P T V R Q R C G R A S G \* A P  
 TTCACTGGCCTGCCGCCGACAGTGGCGCAGCGATGTGCTCGAGCATCCGGTTGAGCGC  
 2350 2360 2370 2380 2390 2400  
 AAGTGACCGGACGGCGGCTGTACGCCGTGCTACACGAGCTCGTAGGCCCAACTCGCG  
 E S A Q R A S L A A A I H D L M R N L A  
 \* Q G A A G V T R C R H P R A D P Q A G  
 V P R G R R C H P L S T T S C G T S R R

FIGURE 6 (CONT'D)

R P E L P H L G G G V C V R F G H P D R  
 D P S C P T S V E G F A S G S G T R T G  
 T R V A P P R W R G L R Q V R A P G P V  
 CGACCCGAGTTGCCCCACCTCGGTGGAGGGTTTCGCTCAGGTTCCGGCACCCGGACCGG  
 2410 2420 2430 2440 2450 2460  
 GCTGGGCTCAACGGGGTGGAGCCACCTCCCCAAACGACGTCCAAAGCCCCGTGGCCCTGGCC  
 S G L Q G V E T S P N A D P E P V R V P  
 V R T A G G R H L P K R \* T R A G P' G T  
 G S N G W R P P P T Q T L N P C G S R Y<sup>28/43</sup>  
 \* L D L A A I Q R \* V D D F A R G L R D  
 S L T S P R S N G R S T T S L A V C A T  
 A \* P R R D P T V G R R L R S R F A R P  
 TAGCTTGACCTCGCGCGATCCAAACGGTAGGTGACGACTTCGCTCGCGGTTGCGCGAC  
 2470 2480 2490 2500 2510 2520  
 ATCGAACTGGAGCGCGCTAGGTTGCCATCCAGCTGCTGAAGCGAGCGCAACGCGCTG  
 L K V E G R D L P L D V V E S A T Q A V  
 A Q G R R S G V T P R R S R E R N A R G  
 S S R A A I W R Y T S S K A R P K R S R

FIGURE 6 (CONT'D)

R R N G A S A R L M M T I P A V V A A T  
 A A T A P A P A \* \* \* R F R R S S R R P  
 P Q R R Q R P L D D D S G R R G D Q  
 CGCCGAACGGCCAGCGCCGCTTGATGATGACGATTCCGGCGGTGTCGGCGGACC  
 2530 2540 2550 2560 2570 2580  
 GCGCGTTCGCGGTCGGGCGAACTACTACTGCTAAGGCCGCCAGCAGCGCGCTGG  
 A A V A G A G A Q H H R N R R D D R R G  
 G C R R W R G S S S S E P R R P S W  
 R L P A L A R K I I V I G A T T A A V L

29/43

N A I T V T I P K M I S I C N I V A S T  
 T Q S P \* R F R K \* S A S A T S W R R R  
 R N H R D D S E N D Q H L Q H R G V D V  
 AACGCAATCACCGTGACGATTCCGAAATGATCAGCATCTGCAACATCGTGGCGTCGACG  
 2590 2600 2610 2620 2630 2640  
 TTGCGTTAGTGCACTGCTAAGGCTTTTACTAGTCGTAGACGTTGTAGCACCGCAGCTGC  
 V C D G H R N R F H D A D A V D H R R R  
 R L \* R S S E S F S \* C R C C R P T S T  
 A I V T V I G F I I L M Q L M T A D V N

L P I D R P V T M T S C P F R L G A A S  
 C P S T G R \* R \* R R A R F G S E R P A  
 A H R Q A G D D D V V P V S A R S G Q H  
 -----

## FIGURE 7

1 GAA TTC CAA CCG TCG GTG CAG ATC CAG GTC TAT CAG GGG GAG CGT GAG 48  
Glu Phe Gln Pro Ser Val Gln Ile Gln Val Tyr Gln Gly Glu Arg Glu

49 ATC GCC GCG CAC AAC AAG TTG CTC GGG TCC TTC GAG CTG ACC GGC ATC 96  
Ile Ala Ala His Asn Lys Leu Leu Gly Ser Phe Glu Leu Thr Gly Ile

30/43

97 CCG CCG GCG CCG CGG GGG ATT CCG CAG ATC GAG GTC ACT TTC GAC ATC 144  
Pro Pro Ala Pro Arg Gly Ile Pro Gln Ile Glu Val Thr Phe Asp Ile

145 GAC GCC AAC GGC ATT GTG CAC GTC ACC GCC AAG GAC AAG GGC ACC GGC 192  
Asp Ala Asn Gly Ile Val His Val Thr Ala Lys Asp Lys Gly Thr Gly

## FIGURE 7 (CONT'D)

93 AAG GAG AAC ACG ATC CGA ATC CAG GAA GGC TCG GGC CTG TCC AAG GAA 240  
 Lys Glu Asn Thr Ile Arg Ile Gln Glu Gly Ser Gly Leu Ser Lys Glu

11 GAC ATT GAC CGC ATG ATC AAG GAC GCC GAA GCG CAC GCC GAG GAG GAT 288  
 Asp Ile Asp Arg MET Ile Lys Asp Ala Glu Ala His Ala Glu Glu Asp

31/43

19 CGC AAG CGT CGC GAG GAG GCC GAT GTT CGT AAT CAA GCC GAG ACA TTG 336  
 Arg Lys Arg Arg Glu Glu Ala Asp Val Arg Asn Gln Ala Glu Thr Leu

7 GTC TAC CAG ACG GAG AAG TTC GTC AAA GAA CAG CGT GAG GCC GAG GGT 384  
 Val Tyr Gln Thr Glu Lys Phe Val Lys Glu Gln Arg Glu Ala Glu Gly



FIGURE 7 (CONT'D)

385 GGT TCG AAG GTA CCT GAA GAC ACG CTG AAC AAG GTT GAT GCC GCG GTG 432  
 Gly Ser Lys Val Pro Glu Asp Thr Leu Asn Lys Val Asp Ala Ala Val

433 GCG GAA GCG GAA GGC GGC ACT TGG CCG ATC GGA TAT TTC GGC CAT CAA 480  
 Ala Glu Ala Glu Gly Gly Thr Trp Arg Ile Gly Tyr Phe Gly His Gln

32/43

481 GTC GCG GAT GGA GAA GCT GGG CCA GGA GTC GCA GGC TCT GGG GCA AGC 528  
 Val Gly Asp Gly Glu Ala Gly Pro Gly Val Ala Gly Ser Gly Ala Ser

529 GAT CTA CGA AGC AGC TCA GGC TGC GTC ACA GGC CAC TGG CCG TGC CCA 576  
 Asp Leu Arg Ser Ser Ser Gly Cys Val Thr Gly His Trp Arg Cys Pro

577 CCC CCG CCG CGA GCC GGG CCG TGC CCA CCC CCG CTC GGC 615  
 Pro Arg Arg Arg Ala Gly Arg Cys Pro Pro Arg Leu Gly

33/43

FIGURE 8

5' TCGAACGAGGGCGGTGACCCCGGTGCGGGGCTTCTTGCACTCGGCATAGCGGAGTGCTAAG  
 3' AGCTTGCCTCCCGCACGTGGCCACGCCCCGGAAGACGTGAGCCGTATCCGCTCACGATTC  
 10 20 30 40 50 60

AATAACGTTGGCACTCGCGACCGGTGAGTGCTAGGTCGGGACGGTGAGGCCAGGCCCGTIC  
 TTATTGCAACCGTGAGCGCTGGCCACTCAGGATCCAGCCCTGCCACTCCGGTCCGGGCAG  
 70 80 90 100 110 120

GTCCGACGAGTGCGCAGCGAGGACAACITGAGCCGTCCGTGCGGGCACTGCGCCCGGCC  
 CAGCGTCGCTCACCGTCGCTCCTGTTGAACCTCGGCAGGCAGGCCCGGTGACGCGGGCCGG  
 130 140 150 160 170 180

\* R G C R H P V T P V S S P T R R  
 AGCGTAAGTAGCGGGGTGCGGTCACCCCGGTGACCCCGGTTCATCCCGATCCGGAGGA  
 TCGCATTCATCGCCCAACGGCAGTGCGCCACTGCGGGCAAGTAGGGCTAGGCCTCCT  
 190 200 210 220 230 240

N H F A M A K T I A Y D E E A R R G L E  
 ATCACTTCGCAATGGCCAAAGACAAATTCGTACGACGAAGAGGCCCGTCGCGGCTCGAGC  
 TAGTGAAGCGTTACCGGTTCGTGTAACGCAATGCTGCTCTCCGGGCAAGCGCGGAGCTCG  
 250 260 270 280 290 300

R G L N A L A D A V K V T L G P K G R H  
 GGGGCTTGAACGCCCTCGCCGATGCGGTAAAGGTGACATTTGGGCCCCAAGGCCGCAACG  
 CCCCGAACITGCGGAGCGGCTACGCCATTCCACIGIAACCCGGGTTCCTCCGGCGTIGC  
 310 320 330 340 350 360

V V L E K K W G A P T I T H D G V S T A  
 TCGTCCCTGGAAAAGAAGTGGGTGCCCCCAGCATCACCACGATGGTGTGTCCTCAICGCCA  
 AGCAGGACCTTTCTTACCCACCGGGGTGCTAGTGTGCTTACCAACACAGGTAGCGGT  
 370 380 390 400 410 420

34/43

FIGURE 8 (CONT'D)

```

K E I E L E D P Y E K I G A E L V K E V
AGGAGATCGAGCTGGAGGATCCGTACGAGAAGATCGGCGCCGAGCTGGTCAAAGAGGTAG
TCCTCTAGCTCGACCTCCTAGGCAITGCTCTTCTAGCCGCGGCTCGACCAAGTTCCTCCATC
430      440      450      460      470      480

A K K T D D V A G D G T T A T V L A Q
CCAAGAAGACCGATGACGTCGCCGGTGACGGCACCAAGACGGCCACCGTGTGGCCCAAG
GGTTCCTCTGGCTACTGACGCGGCCACATGCCGTGGTGTCTGCCGTGGCACGACCGGGTCC
490      500      510      520      530      540

A L V R E G L R N V A A G A N P L G L K
CGTTGGTTCGCGAGGCGCTCGGCAACGTCGCGCGCGGCCCAACCCGCTCGGTCTCAAAC
GCAACCAAGCGCTCCCGGACGCGTTGCAGCGCGCGCGGTGGGCGAGCCAGAGTTG
550      560      570      580      590      600

R G I E K A V E K V T E T L L K G A K E
GGGCGATCGAAAGCGCGTGGAGAGGTCACCGAGACCCCTGCTCAAGGGCGCCAAAGGAGG
CGCCGTAGCTTTTCCGGCACCTCTTCCAGTGGCTCTGGGACGAGTTCCTCCGCTTCTCC
610      620      630      640      650      660

V E T K E Q I A A T A A I S A G D Q S I
TCGAGACCAAGGAGCAGATTGCGGCCACCGCAGCGGATTCGGCGGGTGACCAAGTCCATCG
AGCTCTGGTTCCTCGTCTAACCGCGGTGGGTGCTGCTAAAGCCGCCCACTGGTCAGGTAGC
670      680      690      700      710      720

G D L I A E A M D K V G N E G V I T V E
GTGACCTGATCGCCGAGGCGATGGACAAGGTGGGCAACGAGGGCGTCAATCACCCTCGAGG
CACTGGACTAGCGGCTCCGCTACCTGTTCACCCCGTGTCTCCCGCAGTAGTGGCAGCTCC
730      740      750      760      770      780

```

35/43

FIGURE 8 (CONT'D)

E S N T F G L Q L E L T E G M R F D K G  
 AGTCCAACACCTTTGGGCTGCAGCTCGAGCTCACCAGGGGTAIGGGTTCGACAAGGGCT  
 TCAGGTTGTGGAAACCCGACGTCGAGCTCGAGTGGCTCCCATACGCCAAGCTGTTCGCCGA  
 790 800 810 820 830 840

Y I S G Y F V T D P E R Q E A V L E D P  
 ACATCTCGGGTACTTCGIGACCGACCCGGAGCGTICAGGAGGGGTCCTGGAGGACCCCT  
 TGTAGAGCCCCCATGAAGCAGCTGGCTGGGCTCGCAGTCTCCGCCAGGACCTCCTGGGGA  
 850 860 870 880 890 900

Y I L L V S S K V S T V K D L L P L L E  
 ACATCTGCTGCTCAGCTCCCAAGGTGTCCACTGTCAAGGATCTGCTGCCGCTGCTCGAGA  
 TGTAGGACGACCCAGTCGAGGTTCCACAGGTGACAGTTCCTAGACGACGCGGACGAGCTCT'  
 910 920 930 940 950 960

K V I G A G K P L L I I A E D V E G E A  
 AGGTCAICGGAGCCGGTAAGCCGCTGCTGATCAICGCCGAGGACGTCGAGGGCGAGGCGC  
 TCCAGTAGCCCTCGGCCATTTCGGCGACGACTAGTAGCGGCTCCTGACGCTCCCGCTCCGCG  
 970 980 990 1000 1010 1020

L S T L V V N K I R G T F K S V A V K A  
 TGTCCACCCCTGGTCTCAACAAGATCCCGGACCTTCAAGTCCGCTGGCGGTCAAGGCTC  
 ACAGGTGGACCCAGCAGTTGTCTAGGCGCCGTGGAAGTTCAGCCACCGCCAGTTCGAG  
 1030 1040 1050 1060 1070 1080

P G F G D R R K A M L Q D M A I L T G G  
 CCGGCTTCGGCGACCCGCAAGGCGATGCTGCAGGATATGGCCATCTCACCGGTGGTC  
 GGCCGAAGCCGCTGGCGGCTTCGCTACGACGCTCTATACCGGTAGAGTGGCCACCCAG  
 1090 1100 1110 1120 1130 1140

Q V I S E E V G L T L E H A D L S L L G  
 AGGTGATCAGCGAAGAGGTTCGGCTTGACGCTGGAGAACGCCGACCTGTCTGCTGCTAGGCA  
 TCCACTAGTCGCTTCCTCAGCCGAGTGGACCTCTTGGCGCTGGACAGCGACGATCCGT  
 1150 1160 1170 1180 1190 1200



37/43

FIGURE 8 (CONT'D)

L E P G V V A E K V R N L P A G H G L N  
 TGGAGCCGGCGGTGGTGGCCGAGAGGTGGCAACCTGGCCGCTGGCCACGGACTGAACG  
 ACCTCGGCCCGCACCAACCGGCTCTTCCACGGCTTGGACGGCCGACCGGTGCTGACTTGC  
 1830 1840 1850 1860 1870 1880  
 A Q T G V Y E D L L A A G V A D P V K V  
 CTCAGACCGGTGTCTACGAGGATCTGCTCGCTGCCGCGCTTGCTGACCCGGTCAAGGTGA  
 GAGTCTGGCCACAGATGCTCCTAGACGAGCGGCGCCGCAACGACTGGGCCAGTTCCTACT  
 1690 1700 1710 1720 1730 1740  
 T R S A L Q N A A S I A G L F L T T E A  
 CCGTTCGGCGCTGCAGAAATGCGCGCTCCATCGCGGGCTGTCTTCTGACCAACCGAGGCCG  
 GGGCAAGCCGCGACGTCCTACGCCGCGAGGTAGCGCCCGGACCAAGGACTGGTGGCTCCGGC  
 1750 1760 1770 1780 1790 1800  
 V V A D K P E K E K A S V P G G D M G  
 TCGTTGCCGACAAAGCCGGAAGGAGAGGCTTCCGTTCCCGGTGGCGCGACATGGGTG  
 AGCAACGGCTGTTCGGCTTTTCTCTTCCGAAGGCAAGGGCCACCGCGCTGTATCCAC  
 1810 1820 1830 1840 1850 1860  
 G M D F \*  
 GCATGGATTCTGACCCCGGCGAGAGTCCGACGAGGAGCCCGTCCCTTTGTGGGGCC  
 CGTACCTAAAGACTGGGGCCGCTCTTCAGCGTCGCTCCTCGGGCCAGGGAAACACCCCGG  
 1870 1880 1890 1900 1910 1920  
 GGGCTCCTCTGGTGGGAGCTACGGTACCGGAGAACACCAACGAGTCGTGTAGGCAACCTT  
 CCGAGGAGACCAACCTCGATGCCATGGCTCTTGTGGTGGTCAACATCCGTTGGAA  
 1930 1940 1950 1960 1970 1980  
 TGGCCGCTGTGGGCGAGTCGGGGCCGCGTCTCGGTGCAGCAGCGCGGATGGGTACGA  
 ACCGGGACACCCGCTCAGCCCCCGGCGCAGAGCCACGTCGTGCGCGCCCTACCCATGCT  
 1990 2000 2010 2020 2030 2040

38/43

FIGURE 8 (CONT'D)

CACCGCAGCGGGGTGTCGTCATCGGGGCTCGCTCCGACGCCCTGGGCACGGCCGTCGA  
 GTGGCGTCGCCGCCACAGCAGTAGCCCGGACGCAGGCTGCGGACCCGTGCCGCGCAGCT  
 2050 2060 2070 2080 2090 2100  
 CGATCAGCGAGTAGCCGCTAGGATCGGATGGCGGCCACAAACAGGGTGACTTCGCTGCGGT  
 GCTAGTCGCTCATCGGCGATCCTAGCCTACCGCCGGTGTTGTCCACTGAAGCGACGCCA  
 2110 2120 2130 2140 2150 2160  
 GGGCCAGGTTTGGCCGGTACGACCCCGGATCAGGCCGACGTCGACCACTGCCCGGGGTC  
 CCGGTCCAAACGGCGCATGCTGGGGCTAGTCCGGCTGCAGCTGGTGACGGGCCCCCAG  
 2170 2180 2190 2200 2210 2220  
 CATCGGGCGGTCGGGGAGTTCGGCGCAGCACCGGCTCGACTGCCACCGTGTGCACGCGAT  
 GTAGCCCCGGCAGCCCCTCAAGCGGCTCGTGGCCGAGCTGACGGTGGCACACGTCGCGCTA  
 2230 2240 2250 2260 2270 2280  
 2290 2300 2310 2320 2330 2340  
 GGCCATCATCGACGGTGATCAGGTAAGCGAAGCGGTAGTCGGGCAAGCGCGGCCAGCC  
 CCGGTAGTACCTGCCACTAGTCCATTGCGTTGCCCATCAGCCCCGTTCCGCGCGGTCGG  
 2350 2360 2370 2380 2390 ... 2400  
 GTTTGAGGTCTACCTTTTGGCACCCACCGGATTCGAGGATAGCGGCCCGATGTGTATC  
 CAACTCCAGATGGAAAACCGTGGTGCCCTAAGCTCCTATCCGCGGCTACACAAATGAG  
 2410 2420 2430 2440 2450 2460  
 CGAACCGACCGGCTGCCCGATCCGGGGCTGGCGTAGCGGATTCGGCGTCCGGGCTCGG  
 GCTTGGCTGGCCGACGGGCTAGCGGCCCGACCGCATCCGCCCTAAGCGCCAGCCCCGAGCC  
 S G V P Q G I R P S A Y A S E R D P S P  
 2470 2480 2490 2500 2510 2520  
 GTAGAAGTTCGACTTGGGGATGCCGGAGCCGGGGTACTCGGCTCAGCGCAGCGGTAT  
 CATCTTCAAGCTGAACCCCTACGGCTCGGCCCCCATGAGCCGAGTGGTGCCGCCATAA  
 Y F H S K P I G S G P I S P E R V A T H

39/43

FIGURE 8 (CONT'D)

2530 2540 2550 2560 2570 2580  
 CCGCAAGCCCCGAGTCGTTGCTGCCCGAGTIGACGAAGCTCGGGTAGCTGGTGCCAGGGCT  
 GCGGTTCGGGCTCAGCAACGACGGGCTCAACTGCTTCGAGCCCCATCGACCAACGGTCCCCGA  
 R L G S D H S G S H V F S P Y S T G P S  
  
 2590 2600 2610 2620 2630 2640  
 TCTAAGCCCCGGGTTTGGCCCGGAGCCAGCCGCGGCACIGCCGCTACCGGGGTTTCGGGTT  
 AGATTCCGGGCCCCAAACGCGGCTCGGTCCGCGCGCTGACGGCGATGGCCCCCAAGCCCCAA  
 R L G P H A G S G A A S G S G P H P N  
  
 2650 2660 2670 2680 2690 2700  
 GCCTGAGTCCAGGCCGCCAACAGGAGCACIGGCCGGGCGGCGACGGCGTGTGGTTCAG  
 CGGACTCAGGTCCGGCGGTTGTCTCTGTGACCGGCCCGCGCTGCCCGCACAAACCCAGTC  
 G S D L G G V P A S A P A A V P T N T L  
  
 2710 2720 2730 2740 2750 2760  
 GCCCGAGTTGAGGACGTTCCGCCAGGCCGTTGGAGACCGCCCGTTGATCCGAGGGCGGA  
 CCGGCTCAACTCCTGCAAGCGGTCCGGCACAACTCTGGCGGGCAACTAGGCTCCCCGCT  
 G S N L V H A L G H Q L G G T S G L A S  
  
 2770 2780 2790 2800 2810 2820  
 GCGGAGGATGCCCGAACITCAAAGCCGCCGTGCTCATGCCCGCGGTGGCGTAGCCGGCGGA  
 CCGTCTCCTACGGGCTTGAGTTTCGGCGGCACGAGTACGGCGGCCACCGCATCGGCCGCT  
 A L I G S S L A A T S M G G T A Y G A S  
  
 2830 2840 2850 2860 2870 2880  
 GGTGACCAAGGCCGCCCTCCGAGGCCAGCCGCGCTTCCCTAAGCGGGCGTTTTCATCCCCCGC  
 CGACTGGTTCGGCGGAGGCTCGGTCCGGCGGAGGATTCCCGCGCAAAACGTAGGGGCG  
 S V L A A E S G A A S G L A A H Q M G A  
  
 2890 2900 2910 2920 2930 2940  
 GTTCCAGAAGCTGGTGTGAGGCTGCCCTGCGCTGCCGAGGCCCGCGTTGATTGTCCCCCGA  
 CAAGGTCTTCGACCCACAACCTCCGACGCGACGCGCTCCGGCGCAACTAACAGGGGCT  
 H W F S T H L S G A S G L G A H I T G S



40/43

## FIGURE 8 (CONT'D)

2950 2980 2970 2990 3000  
 GGTCCCGATGCCGCTGTTTCAGGGAGCCCGAATTCCTCCGATGTTTCCGCTGCCCGGA  
 CCAGGGCTACGGCGACAAAGTCCCTCGGGCTTAAGGGCTACGGCTACAAAGGCGACGGCCT  
 T G I G S N L S G S N G I G I N G S G S  
  
 3010 3020 3030 3040 3050 3060  
 GTTGAATAAGCCGACGTTGCCGGTCCCGAGTTCCTCCGAAGCCGATGTTCGGCTACCCGA  
 CAACITATTCGGCTGCAACGGCCACGGGCTCAAGGGCTTCGGCTACAAACGGCATGGGCT  
 H F L G V N G T G S N G F G I N G S G S  
  
 3070 3080 3090 3100 3110 3120  
 GTTGAAGCCGCCGAAACCCATCTGGTGATCACCGGTGATCCCGAACCCGATATTCCCGCT  
 CAACITTCGGCGCTTTGGGTAGACCACCTAGTGGCCACTAGGGCTTGGGCTATAAGGGCGGA  
 N F G G F G M Q H D G T I G F G I N G S  
  
 3130 3140 3150 3160 3170 3180  
 ACCGGTGTTGCCGAAGCCGATATTCCTCGTCCCGAGGTTCGGAGGCCCGAGGTTGCCCGCT  
 TGGCCACAACGGCTTCGGCTATAAGGGCAGCGGCTCCAAACGGCTCCGGGTCCAAACGGCGGA  
 G T N G F G I N G D G L N G L G L N G S  
  
 3190 3200 3210 3220 3230 3240  
 GCCGGTGTTGCCGCTGCCGATGTTGGCCGGTGGTTCGGCTGCGCGATGTTGTTGTT  
 CGGCCACAACGGCGAGCGCTACAACGGCCACGGCCACAACGGCGAGCGGTACAAACAA  
 G T N G S G I N G T G T N G S G I N N H  
  
 3250 3260 3270 3280 3290 3300  
 GCCGATGTTGTTGGCCGATGTTGTTGTTGGCCGATGTTCGGCTGCGCGGTGTTGCCCGAA  
 CGGCTACAACAACAGCGCTACAACAACAGCGGTACAACGGCGAGCGGCCACAACGGCTT  
 G I N N N G I N N N G I N G S G T N G F  
  
 3310 3320 3330 3340 3350 3360  
 GCCCAGATIGATCTGGCCGTTCTTGGCCGATGTTCGATGCCGAGGTTCGCCAAGACCTGCTG  
 CGGGTCTAAGTACCGCGCAAGAACGGCTACAGCTACGGCTCCAAAGGCGTTCCTGGACGAC  
 C I H I N G N G C T D I G I H R I V Q .Q

41/43

FIGURE 8 (CONT'D)

3370 3380 3390 3400 3410 3420  
 CCAGGGCCAGTTGTGCGACGGCCGAGCGCATCGAAGTGGTAACGAGCCATCGCCCGC  
 GGTCCCGCGGTCAACACGCTGCCCGGCTGTGCGTAGCTTCACCATTTGGTCGGTAGCGGCG  
 W P A L Q A V A A S A D F H Y G A M A A  
 3430 3440 3450 3460 3470 3480  
 CACGTCCCAATGCCACATTTGCTCGTAIGCCGCCCTCGACGTCCATGAGCGCCGGAGCGTT  
 GTGCAGGTACGGGTGTAAACGAGCATACGGCGGAGCTGCAGGTACTCGGCGCTCGCAA  
 V D L A W M Q E Y A A E V D H L A P A H  
 3490 3500 3510 3520 3530 3540  
 CTGCCCCAACCCAGTTCTGCTAGCTGCCAGCAGCTGCATCAGGCCACGATTGGCCGCTACCAC  
 GACGGGTTTGGTCAAGCATCGACGGTCGTGACGTAGTCCGGTGTCTAACCGGCGATGGTG  
 Q G F W N T A A L L Q M L G R N A A V V  
 3550 3560 3570 3580 3590 3600  
 TGCCGGCTGCACGGTGGCCGCCAGCGCCGCTCGAACCGGCTCGCTGTGTGCCATGGCCIG  
 ACGCCCGACGTGCCACCGCGGTCTCGCGCGGAGCTTGGCCAGCGACACGGTACCGGAC  
 A P Q V T A A L A A E F A T A T A M A Q  
 3610 3620 3630 3640 3650 3660  
 TGCGGGCCGCTTGTTCGGCTGCGCTGCCCGCGTGTGCTGAGCCAGGCTAGGTACTGGGTTC  
 ACGCCGGCGAACAAGCGCGGACCGGCGGCGGACGACTCGGTCCGATCCATGACCCCAACG  
 A A A Q E A Q A A A T S L W A L Y Q T A  
 3670 3680 3690 3700 3710 3720  
 GACGGCCATCATCGCCCGCGGACCGGACCCAGCCAGCGGCCACTAGTCAGTTCGGAIGT  
 CTGCGCGGTAGTAGCGCGCGGCTGCTGCGGTCCGCGGTGATCAGTCAAGCCTACA  
 V A M M A A A S P G L W A G S T L E S T  
 3730 3740 3750 3760 3770 3780  
 GACGGAGCCAAAGCGACGCTATTGACCGCGAGCAATCTTCGGCCAGCTCGCCCGGCGGT  
 CTGCCCTCGGTTCGCTCGGATAACTGCGCTCGTTAAGAACCGGCTCGAGCGGGTCCGCCA  
 V S G L S A I S A L L E A L E G W A T

FIGURE 8 (CONT'D)

3790 3800 3810 3820 3830 3840  
 GGCCGCAGCAATTAGCGGTCGCCGACCCGGGACCGGCAACATCAGTGCCGAAATTGATCTC  
 CCGCGCTCGTTAATCGCCAGGCTGGGCCCTGGCCGTTTGTAGTCACGGCTTAACCTAGAG  
 A A A I L P G S G P G A F M L A S H I E  
 3850 3860 3870 3880 3890 3900  
 TGGCGGCAACCACGCAAAATGCGGGCTTGTACGCCGATCCAACTTAACTGTACGGACCG  
 ACCGCCGTGGTGGCTTTACGCCCGGAACAGTCGGCTAGGTGAATTGACAGTCGCTGGC  
 P P L W A F H P S T L R D L K V T L S R  
 3910 3920 3930 3940 3950 3960  
 TTGCCGTGGCGGTATCGGCACCTTCAATACCACCTCATCTTTGGGGTCAICTTTGGAGCGCC  
 AACGGCACCGCCATAGCCGTTGAAGTTATGGTGAGTAGAAACCCAGTAGAACCCTCGCGG  
 Q R P P I P V E I G S M K P T M K P A G  
 3970 3980 3990 4000 4010 4020  
 CCTAGGAACCGCCAGCTTACCTAGTCCCGGTAGGGCCGACCTGGCGCGCCGGGATGCAGC  
 GGATCCTTGGCGGTGGAATGGATCAGGGGCCCATCCCGGCTGACCGCGGCCCTACGTCG  
 R P V A L K G L G P Y P G V P P R S A A  
 4030 4040 4050 4060 4070 4080  
 TGAGGGTCTGCCACCTGCC'CGTAATGTGCTGGTATGGCAAGCACCGACCGCGCGGCC  
 ACTCCAGACCGTGGACGGGGCATTACAGCGACCATACCGTTCTGGCTGGCCTGCGGCGG  
 S P R G G A G Y H R Q Y P L C R R R P G  
 4090 4100 4110 4120 4130 4140  
 AAGAGTGTCTCCGCGACCGGTTACCCCGGTGATCGAACAATGTGCGACGAACCTCACCAGC  
 TTCICAACGAGGCTCTCGCAAGTGGCCCACTAGCTTGTACAGCTGCTTGTAGTGGCTGC  
 L T A G R R T \*  
 4150 4160 4170 4180 4190 4200  
 GCCTCACCGACCAACTCGCCTGTCTACCGCCCGACCCCGACGGCCCAACAGCAATTGCGTGGC  
 CGGAGTGGCTGGTTGAGCGGACGATGGCGGCTGGGGTGGGGTGTGCTGTAACGCACCG

43/43

## FIGURE 8 (CONT'D)

4210	4220	4230	4240	4250	4260
TGCTCTGGCACAGCGCCCGGGTGCAGGATATACAGGTCGCCCATGTGGCCGCGGTGGAAG					
ACGAGACCGGTGTGCGGGCCACGTCCTATATGTCAGCGGGTACACCGGCCGCACCTTC					
4270	4280	4290	4300	4310	4320
AGGTGTGGACCCCGGACGGTTGGGTGGACCGCTTTGGGTTAGATCTGCCCGCGGCACGACA					
TCCACACCTGGGCGCTGCCAACCACCTGGCGAAACCCAACTCTAGACGGCGCGCTGCTGT					
4330	4340	4350	4360	4370	
CCGGATATGGACACCGTCCCAGGATGTGGCGAAGGTACGGGCACCCGCCGACGGAATTC					
GGCCTATACCTGTGGCAGGGCTCCTACACCGCTTCCATGCCCGTGGCGGCTGCCTTAAG					

3'  
5'